[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1499
1. Hoe SL, Lee ES, Khoo AS, Peh SC: p53 and nasopharyngeal carcinoma: a Malaysian study. Pathology; 2009;41(6):561-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of Epstein-Barr virus (EBV) was determined by in situ hybridisation using an EBER probe. p53 protein expression was detected using immunohistochemistry.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Regulation, Neoplastic. Nasopharyngeal Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. DNA Mutational Analysis. DNA, Neoplasm / analysis. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / genetics. Epstein-Barr Virus Infections / pathology. Exons. Female. Fluorescent Antibody Technique, Indirect. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Humans. In Situ Hybridization. Male. Middle Aged. Polymorphism, Single-Stranded Conformational. RNA-Binding Proteins / analysis. Ribosomal Proteins / analysis. Young Adult

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19900105.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 0 / Tumor Suppressor Protein p53; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


2. Ren YL, Wang HY, Zhou XY, Shan BE, Yang WT, Shen L, Shi DR: [Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2010 May;45(5):367-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The purpose of this study was to evaluate gene amplification by chromogenic in situ hybridization (CISH) and the protein expression of Her-2/neu gene in patients with uterine papillary serous carcinoma (UPSC) and to determine its prognostic value.
  • METHODS: Thirty-six patients with confirmed pathologic diagnosis of UPSC in Cancer Hospital of Fudan University from Jan.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Aged, 80 and over. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Female. Humans. Immunohistochemistry. In Situ Hybridization / methods. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646447.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


3. Dede M, Gezginç K, Ulubay M, Alanbay I, Güran S, Yenen M: A breast cancer patient with pelvic and gastric malignancy after adjuvant tamoxifen treatment for breast cancer. Eur J Gynaecol Oncol; 2008;29(2):200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Aged. Carcinoma in Situ / chemically induced. Endometrial Neoplasms / chemically induced. Female. Humans. Middle Aged. Stomach Neoplasms / chemically induced. Uterine Cervical Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459568.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


Advertisement
4. Bethel CR, Faith D, Li X, Guan B, Hicks JL, Lan F, Jenkins RB, Bieberich CJ, De Marzo AM: Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res; 2006 Nov 15;66(22):10683-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion.
  • Prior studies of NKX3.1 mRNA and protein in human prostate cancer and prostatic intraepithelial neoplasia (PIN) have been conflicting, and expression in focal prostate atrophy lesions has not been investigated.
  • Fluorescence in situ hybridization showed that no cases of atrophy had loss or gain of 8p, 8 centromere, or 8q24 (C-MYC) and only 12% of high-grade PIN lesions harbored loss of 8p.
  • Monoallelic deletions on chromosome 8p are associated with more advanced invasive and aggressive disease.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Deletion. Chromosomes, Human, Pair 8 / genetics. Homeodomain Proteins / biosynthesis. Prostate / pathology. Prostatic Intraepithelial Neoplasia / genetics. Prostatic Neoplasms / genetics. Transcription Factors / biosynthesis
  • [MeSH-minor] Adult. Aged. Atrophy / genetics. Atrophy / metabolism. Atrophy / pathology. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Chromosome 8p.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17108105.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA94818-04; United States / NCI NIH HHS / CA / P50CA58236; United States / NCI NIH HHS / CA / R01CA84997; United States / NIDDK NIH HHS / DK / R01DK54067
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / NKX3-1 protein, human; 0 / RNA, Messenger; 0 / Transcription Factors
  •  go-up   go-down


5. Zhang XQ, Huang XF, Mu SJ, An QX, Xia AJ, Chen R, Wu DC: Inhibition of proliferation of prostate cancer cell line, PC-3, in vitro and in vivo using (-)-gossypol. Asian J Androl; 2010 May;12(3):390-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / pharmacology. Contraceptive Agents, Male / pharmacology. Gossypol / pharmacology. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antigens, CD31 / metabolism. Apoptosis / drug effects. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Humans. In Situ Nick-End Labeling. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Microvessels / drug effects. Microvilli / drug effects. Microvilli / ultrastructure. Neovascularization, Pathologic / drug therapy. Proliferating Cell Nuclear Antigen / metabolism. Proto-Oncogene Proteins c-bcl-2. Tetrazolium Salts. Thiazoles. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. Gossypol .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3791-9 [11268456.001]
  • [Cites] Anticancer Res. 2009 Jun;29(6):2179-88 [19528479.001]
  • [Cites] Biochem Pharmacol. 2003 Jul 1;66(1):93-103 [12818369.001]
  • [Cites] J Med Food. 2003 Winter;6(4):291-9 [14977436.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):91-100 [15015581.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):815-23 [15361189.001]
  • [Cites] Cancer Res. 1987 Aug 15;47(16):4243-7 [2440560.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Semin Diagn Pathol. 1993 Nov;10(4):302-13 [7511250.001]
  • [Cites] Oncology. 1995 Mar-Apr;52(2):134-9 [7854773.001]
  • [Cites] Br J Cancer. 1997;76(1):21-8 [9218727.001]
  • [Cites] Melanoma Res. 1997 Oct;7(5):364-72 [9429219.001]
  • [Cites] Semin Urol Oncol. 1998 Aug;16(3):118-23 [9741415.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):940-4 [9764587.001]
  • [Cites] Cancer Lett. 1999 Jan 29;135(2):171-80 [10096426.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(4):361-71 [10453280.001]
  • [Cites] Urology. 1999 Sep;54(3):479-85 [10475358.001]
  • [Cites] Mol Cancer Ther. 2005 Feb;4(2):197-205 [15713891.001]
  • [Cites] Mol Cancer Ther. 2005 Jul;4(7):1096-104 [16020667.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9350-9 [16227586.001]
  • [Cites] Pancreas. 2005 Nov;31(4):317-24 [16258364.001]
  • [Cites] Neoplasia. 2006 Mar;8(3):163-72 [16611409.001]
  • [Cites] Anticancer Res. 2006 May-Jun;26(3A):1925-33 [16827126.001]
  • [Cites] J Med Chem. 2006 Oct 19;49(21):6139-42 [17034116.001]
  • [Cites] Life Sci. 2007 Jan 30;80(8):767-74 [17156797.001]
  • [Cites] Pharmacol Res. 2008 Nov-Dec;58(5-6):323-31 [18840529.001]
  • [Cites] Eur Cytokine Netw. 2008 Dec;19(4):176-84 [19103523.001]
  • [Cites] J Surg Res. 2009 Jun 1;154(1):9-12 [19084241.001]
  • [Cites] Scand J Urol Nephrol. 2001 Dec;35(6):437-52 [11848422.001]
  • (PMID = 20081872.001).
  • [ISSN] 1745-7262
  • [Journal-full-title] Asian journal of andrology
  • [ISO-abbreviation] Asian J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Contraceptive Agents, Male; 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue; KAV15B369O / Gossypol
  • [Other-IDs] NLM/ PMC3739255
  •  go-up   go-down


6. Søreide K, Immervoll H, Molven A: [Precursors to pancreatic cancer]. Tidsskr Nor Laegeforen; 2006 Mar 23;126(7):905-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pancreatic adenocarcinoma is a relatively frequent cancer with an extremely poor prognosis.
  • Until recently, the natural history of pancreatic adenocarcinoma has not been possible to study, but the identification of precursor lesions (pancreatic intraepithelial neoplasia, PanIN) has lead to a better understanding of the stepwise morphological and genetic alterations involved in the development of invasive adenocarcinoma.
  • RESULTS AND INTERPRETATION: PanINs are established as designation of histological precursor lesions to pancreatic adenocarcinoma.
  • PanIN grade I to III represent stepwise morphological alterations in the pancreatic ductal epithelium, from early neoplasia (PanIN I and II), via carcinoma in situ (PanIN III) to the development of invasive ductal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Biomarkers, Tumor / genetics. Disease Progression. Genes, Tumor Suppressor. Humans. Prognosis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554881.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 36
  •  go-up   go-down


7. Bergman JJ, Tytgat GN: New developments in the endoscopic surveillance of Barrett's oesophagus. Gut; 2005 Mar;54 Suppl 1:i38-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with a Barrett's oesophagus are at risk for developing an adenocarcinoma of the distal oesophagus.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Esophageal Neoplasms / diagnosis. Esophagoscopy / methods. Precancerous Conditions / diagnosis
  • [MeSH-minor] Biomarkers / analysis. Esophagus / pathology. Humans. In Situ Hybridization, Fluorescence / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2000 May;51(5):560-8 [10805842.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1028-32 [9672324.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Feb;13(2):97-9 [11246628.001]
  • [Cites] Gastrointest Endosc. 2001 Mar;53(3):333-5 [11231393.001]
  • [Cites] Mayo Clin Proc. 2001 Apr;76(4):438-46 [11322362.001]
  • [Cites] Gastrointest Endosc. 2001 May;53(6):559-65 [11323579.001]
  • [Cites] Gastrointest Endosc. 2001 May;53(6):642-50 [11323596.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):379-88 [11331954.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1620-9 [11375944.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • [Cites] Chest Surg Clin N Am. 2002 Feb;12(1):1-13, vii [11901923.001]
  • [Cites] Gastrointest Endosc. 2002 May;55(6):641-7 [11979244.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Feb;17 Suppl:S85-104 [12000596.001]
  • [Cites] Gastroenterology. 2002 Jun;122(7):1800-7 [12055587.001]
  • [Cites] Expert Rev Mol Diagn. 2002 Jul;2(4):312-20 [12138495.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):6071-81 [12203119.001]
  • [Cites] Lancet. 2002 Nov 16;360(9345):1587-9 [12443613.001]
  • [Cites] Gut. 2003 Jan;52(1):24-7 [12477754.001]
  • [Cites] Am J Pathol. 1988 Apr;131(1):53-61 [3354644.001]
  • [Cites] Surg Oncol. 1995 Jun;4(3):163-71 [7582189.001]
  • [Cites] Am J Gastroenterol. 1996 May;91(5):853-63 [8633572.001]
  • [Cites] Gastroenterology. 1996 Jul;111(1):93-101 [8698231.001]
  • [Cites] Gastroenterology. 1997 Jun;112(6):1787-97 [9178668.001]
  • [Cites] Endoscopy. 2000 Dec;32(12):921-30 [11147939.001]
  • (PMID = 15711007.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 27
  • [Other-IDs] NLM/ PMC1867795
  •  go-up   go-down


8. Bulk S, Berkhof J, Bulkmans NW, Zielinski GD, Rozendaal L, van Kemenade FJ, Snijders PJ, Meijer CJ: Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer; 2006 Jan 16;94(1):171-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands.
  • We present the type-distribution of high-risk human papillomavirus (HPV) types in women with normal cytology (n=1467), adenocarcinoma in situ (ACIS) (n=61), adenocarcinoma (n=70), and squamous cell carcinoma (SCC) (n=83).
  • Cervical adenocarcinoma and ACIS were significantly more frequently associated with HPV18 (OR(MH) 15.0; 95% CI 8.6-26.1 and 21.8; 95% CI 11.9-39.8, respectively) than normal cytology.
  • Human papillomavirus16 was only associated with adenocarcinoma and ACIS after exclusion of HPV18-positive cases (OR(MH) 6.6; 95% CI 2.8-16.0 and 9.4; 95% CI 2.8-31.2, respectively).
  • These results suggest that HPV18 is mainly a risk factor for the development of adenocarcinoma whereas HPV16 is associated with both SCC and adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Adenocarcinoma / virology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / virology. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / etiology. Uterine Cervical Neoplasms / virology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2000 Nov;36(17):2244-6 [11072213.001]
  • [Cites] Int J Cancer. 2005 Nov 1;117(2):177-81 [15900579.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jan-Feb;11(1):39-48 [11285032.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):398-404 [11487272.001]
  • [Cites] J Clin Microbiol. 2002 Mar;40(3):779-87 [11880393.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2114-9 [11966386.001]
  • [Cites] Lancet. 2003 Jan 4;361(9351):40-3 [12517465.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):63-73 [12556961.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] Am J Obstet Gynecol. 2003 Mar;188(3):657-63 [12634637.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):101-5 [12838308.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7215-20 [14612516.001]
  • [Cites] J Pathol. 2003 Dec;201(4):535-43 [14648656.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1871-6 [14667741.001]
  • [Cites] J Clin Virol. 2004 Apr;29(4):271-6 [15018855.001]
  • [Cites] J Clin Pathol. 2004 Apr;57(4):388-93 [15047743.001]
  • [Cites] Int J Cancer. 2004 May 20;110(1):94-101 [15054873.001]
  • [Cites] Int J Epidemiol. 1995 Apr;24(2):300-7 [7635589.001]
  • [Cites] J Clin Microbiol. 1997 Mar;35(3):791-5 [9041439.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):268-75 [15688404.001]
  • [Cites] J Infect Dis. 2005 Jun 1;191(11):1808-16 [15871112.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1157-64 [15894666.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1066-71 [16030304.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9 [16030305.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1906-15 [11283122.001]
  • (PMID = 16404371.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361088
  •  go-up   go-down


9. Raspollini MR, Fambrini M, Marchionni M, Baroni G, Taddei GL: In situ adenocarcinoma and squamous carcinoma of uterine cervix. Pathological and immunohistochemical analysis with cytokeratin 13. Eur J Obstet Gynecol Reprod Biol; 2007 Oct;134(2):249-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ adenocarcinoma and squamous carcinoma of uterine cervix. Pathological and immunohistochemical analysis with cytokeratin 13.
  • OBJECTIVES: The aim of the study was the pathological and immunohistochemical analysis of cytokeratin 13 (CK13) in intraepithelial cervical tumors.
  • STUDY DESIGN: We studied 415 in situ squamous carcinomas and 13 in situ mucinous cervical type adenocarcinomas of the uterine cervix.
  • RESULTS: 3% of the squamous carcinoma patients recurred during the follow-up period, while the percentage of recurrence of in situ adenocarcinoma patients was 7.6%.
  • The percentage of recurrence was high among the cases with positive borders independently from their histopathologic type (14.3% in the squamous carcinomas versus 50% in the adenocarcinomas), compared to cases with negative edges (2.3% in the squamous carcinomas versus 0% in the adenocarcinomas).
  • We observed CK13 positive staining in cervical squamous tumors and in mucinous cervical type adenocarcinomas, while there was no positive staining in non-neoplastic cervical glandular elements.
  • CONCLUSION: CK13 positive immunostaining among in situ squamous and in situ mucinous cervical type adenocarcinoma cases adds additional evidence to data supporting a common origin of the two lesions.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Carcinoma in Situ / metabolism. Carcinoma, Squamous Cell / metabolism. Keratin-13 / metabolism. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949723.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Keratin-13
  •  go-up   go-down


10. Kim JH, Park JY, Kim DY, Kim YM, Kim YT, Nam JH: The role of loop electrosurgical excisional procedure in the management of adenocarcinoma in situ of the uterine cervix. Eur J Obstet Gynecol Reprod Biol; 2009 Jul;145(1):100-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of loop electrosurgical excisional procedure in the management of adenocarcinoma in situ of the uterine cervix.
  • OBJECTIVES: To evaluate the occurrence of residual or recurrent disease after loop electrosurgical excisional procedure (LEEP) for adenocarcinoma in situ (AIS) of the uterine cervix.
  • STUDY DESIGN: Records of 78 patients with a histological diagnosis of AIS of uterine cervix on LEEP who were treated and followed at our center between 1992 and 2008 were, retrospectively, reviewed.
  • Of the 47 patients with negative margins, 30 underwent subsequent hysterectomy and residual AIS, including 1 invasive adenocarcinoma, was present in 17% (5/30) of patients.
  • Of the 31 patients with positive margins, 29 patients underwent subsequent hysterectomy and residual AIS, including 4 invasive adenocarcinomas, was present in 48% (14/29) of patients.
  • CONCLUSIONS: The incidence of residual disease in patients with negative margins after LEEP for AIS of the uterine cervix is low but not negligible.
  • However, positive resection margin carries a higher risk for residual AIS or occult invasive adenocarcinoma, warranting additional LEEP or hysterectomy in these patients.
  • [MeSH-major] Adenocarcinoma / surgery. Electrosurgery / methods. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for adenocarcinoma in situ .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19428171.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 31
  •  go-up   go-down


11. Cimitan A, Burza A, Basile U, Saputo S, Mingazzini P, Stipa F: [Local excision of giant rectal polypoid neoplasms]. Chir Ital; 2008 May-Jun;60(3):345-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parks technique for lower rectal lesions and the T.E.M. technique for lesions localised in the middle and upper rectum offer exceptionally good exposure, allowing radical excision in the case of early low-risk T1 adenocarcinomas (well or moderately differentiated [G1/2] without lymphovascular invasion [L0]).
  • In 3 patients with a preoperative diagnosis of severe dysplasia (Tis) final pathology showed adenoma and for this reason they were included in our study group.
  • Twenty-five (49%) patients had a definitive diagnosis of adenocarcinoma: in situ (pTis) in 22 patients (88%), pT1 in 2 patients (8%) and pT2 in 1 patient (4%).
  • In 26 patients (51%) the diagnosis was adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18709772.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


12. Madisch A, Miehlke S, Bayerdorffer E, Wiedemann B, Antos D, Sievert A, Vieth M, Stolte M, Schulz H: Long-term follow-up after complete ablation of Barrett's esophagus with argon plasma coagulation. World J Gastroenterol; 2005 Feb 28;11(8):1182-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To report the long-term outcome of patients after complete ablation of non-neoplastic Barrett's esophagus (BE) with respect to BE relapse and development of intraepithelial neoplasia or esophageal adenocarcinoma.
  • In none of the patients, intraepithelial neoplasia nor an esophageal adenocarcinoma was detected.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adult. Aged. Argon. Carcinoma in Situ / epidemiology. Cohort Studies. Esophageal Neoplasms / epidemiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Recurrence. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • Hazardous Substances Data Bank. Argon, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15754401.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 67XQY1V3KH / Argon
  • [Other-IDs] NLM/ PMC4250710
  •  go-up   go-down


13. MacGrogan G: [Diagnostic pitfalls in mammary pathology. Case 1. In situ ductal carcinoma of low nuclear grade, with papillary, micropapillary and cribriform architecture]. Ann Pathol; 2009 Jun;29(3):188-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic pitfalls in mammary pathology. Case 1. In situ ductal carcinoma of low nuclear grade, with papillary, micropapillary and cribriform architecture].
  • [Transliterated title] Pièges diagnostiques en pathologie mammaire. Cas no 1. Carcinome canalaire in situ (CCIS) de bas grade nucléaire, d'architecture papillaire, micropapillaire et cribriforme.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Neoplasms, Multiple Primary / diagnosis. Papilloma / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Biomarkers, Tumor / analysis. Carcinoma, Papillary / chemistry. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Cell Nucleus / ultrastructure. Diagnosis, Differential. Female. Humans. Hyperplasia. Keratins / analysis. Membrane Proteins / analysis. Neoplasm Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19619824.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


14. Samuelson E, Nordlander C, Levan G, Behboudi A: Amplification studies of MET and Cdk6 in a rat endometrial tumor model and their correlation to human type I endometrial carcinoma tumors. Adv Exp Med Biol; 2008;617:511-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer is known to be a genetic disease that is both polygenic and heterogeneous, in most cases involving changes in several genes in a stepwise fashion.
  • These data provide strong support for the use of animal model systems for better understanding and scrutinizing of human complex disease of cancer.
  • [MeSH-major] Chromosome Aberrations. Cyclin-Dependent Kinase 6 / genetics. Disease Models, Animal. Endometrial Neoplasms / genetics. Proto-Oncogene Proteins c-met / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Animals. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / secondary. Chromosomes, Human, Pair 7 / genetics. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. Rats. Rats, Inbred BN

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497076.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.11.22 / Cyclin-Dependent Kinase 6
  •  go-up   go-down


15. Casini B, Borgese L, Del Nonno F, Galati G, Izzo L, Caputo M, Perrone Donnorso R, Castelli M, Risuleo G, Visca P: Presence and incidence of DNA sequences of human polyomaviruses BKV and JCV in colorectal tumor tissues. Anticancer Res; 2005 Mar-Apr;25(2A):1079-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, samples obtained from 18 patients with colon rectal carcinoma were probed for the presence of JCV and BKV by three different techniques: Southern blot, PCR and in situ hybridization.
  • [MeSH-major] Adenocarcinoma / virology. BK Virus / genetics. Colorectal Neoplasms / virology. JC Virus / genetics. Polyomavirus Infections / genetics. Tumor Virus Infections / genetics
  • [MeSH-minor] Biopsy. Blotting, Southern. DNA, Viral / genetics. Humans. In Situ Hybridization. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868949.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


16. Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, Waerzeggers Y, Borgman CL, Tawadros S, Li H, Sos ML, Backes H, Shapiro GI, Wolf J, Jacobs AH, Thomas RK, Winkeler A: Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS One; 2008;3(12):e3908
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Somatic mutations of EGFR were found in lung adenocarcinoma that lead to exquisite dependency on EGFR signaling; thus patients with EGFR-mutant tumors are at high chance of response to EGFR inhibitors.
  • [MeSH-minor] Animals. Cell Cycle. Cell Line, Tumor. Down-Regulation. Early Detection of Cancer. Erlotinib Hydrochloride. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Ki-67 Antigen / metabolism. Mice. Receptor, Epidermal Growth Factor / metabolism. Signal Transduction. Treatment Outcome. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Nuklearmedizin. 2003 Aug;42(4):135-44 [12937692.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] J Nucl Med. 1986 Feb;27(2):235-8 [3712040.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4838-48 [9354447.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1334-6 [9809561.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):999-1006 [16741310.001]
  • [Cites] Nat Med. 2006 Jul;12(7):852-5 [16799556.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5659-67 [17020967.001]
  • [Cites] J Nucl Med. 2007 Feb;48(2):277-87 [17268026.001]
  • [Cites] Nat Genet. 2007 Mar;39(3):347-51 [17293865.001]
  • [Cites] Cancer Res. 2007 Dec 1;67(23):11463-9 [18056475.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):2049-55 [18381944.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] N Engl J Med. 2000 Jul 27;343(4):254-61 [10911007.001]
  • [Cites] Nucl Med Biol. 2002 Apr;29(3):281-7 [11929696.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3331-4 [12067968.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2651-7 [12860940.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • (PMID = 19079597.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dideoxynucleosides; 0 / Ki-67 Antigen; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PG53R0DWDQ / alovudine
  • [Other-IDs] NLM/ PMC2592703
  •  go-up   go-down


17. Okoń K, Klimkowska A, Pawelec A, Dobrowolski Z, Kohla Z, Stachura J: Immunophenotype and cytogenetics of mucinous tubular and spindle cell carcinoma of the kidney. Pol J Pathol; 2007;58(4):227-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma / metabolism. Carcinoma / pathology. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Cytogenetics. Female. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pol J Pathol. 2008;59(1):14
  • (PMID = 18459456.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


18. Nara S, Shimada K, Sakamoto Y, Esaki M, Kosuge T, Hiraoka N: Clinical significance of frozen section analysis during resection of intraductal papillary mucinous neoplasm: should a positive pancreatic margin for adenoma or borderline lesion be resected additionally? J Am Coll Surg; 2009 Nov;209(5):614-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In the first intraoperative frozen section analysis, 26 patients were positive for adenoma or borderline lesion, 10 for carcinoma in situ, 2 for cancer cells floating in the duct, and 6 for invasive cancer.
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Pancreatic adenoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19854402.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. East JE, Guenther T, Saunders BP: Novel approaches in colorectal endoscopy: what do we need biopsies for? Pathol Res Pract; 2008;204(7):459-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-neoplastic lesions would be left in situ, and neoplastic lesions resected and disposed of without histopathological assessment.
  • [MeSH-minor] Adenocarcinoma / pathology. Biopsy / economics. Colitis / pathology. Colonic Neoplasms / pathology. Health Care Costs. Humans

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18550296.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


20. Lacour RA, Garner EI, Molpus KL, Ashfaq R, Schorge JO: Management of cervical adenocarcinoma in situ during pregnancy. Am J Obstet Gynecol; 2005 May;192(5):1449-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of cervical adenocarcinoma in situ during pregnancy.
  • OBJECTIVE: Adenocarcinoma in situ (AIS) is a precursor of invasive disease that is being more frequently diagnosed during the reproductive years.
  • The purpose of this study was to review our collective experience managing cervical AIS during pregnancy.
  • STUDY DESIGN: Retrospective medical record review of all women diagnosed with AIS during pregnancy from 1995 to 2004 at 3 academic institutions.
  • Five who received a diagnosis in the early second trimester underwent uncomplicated cold knife conization (CKC) at 14 to 19 weeks' gestation.
  • One patient undergoing postpartum CKC required radical hysterectomy for stage IB1 cervical adenocarcinoma.
  • CONCLUSION: Management of cervical AIS during pregnancy by early second trimester CKC is safe for mother and fetus.
  • [MeSH-major] Adenocarcinoma / surgery. Conization. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / surgery


21. Bhanot U, Heydrich R, Möller P, Hasel C: Survivin expression in pancreatic intraepithelial neoplasia (PanIN): steady increase along the developmental stages of pancreatic ductal adenocarcinoma. Am J Surg Pathol; 2006 Jun;30(6):754-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin expression in pancreatic intraepithelial neoplasia (PanIN): steady increase along the developmental stages of pancreatic ductal adenocarcinoma.
  • Pancreatic ductal adenocarcinoma (PDA) is one of the most aggressive gastrointestinal cancers and is thought to arise from noninvasive precursors-pancreatic intraepithelial neoplasia (PanIN).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma in Situ / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Cell Transformation, Neoplastic / metabolism. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16723855.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


22. Huang SF, Chuang WY, Cheng SD, Hsin LJ, Lee LY, Kao HK: A colliding maxillary sinus cancer of adenosquamous carcinoma and small cell neuroendocrine carcinoma--a case report with EGFR copy number analysis. World J Surg Oncol; 2010;8:92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A tumor with squamous cell carcinoma, adenocarcinoma and SNEC co-existence is extremely rare.
  • CASE PRESENTATION: We present a colliding tumor of squamous cell, adenocarcinoma and SNEC in maxillary sinus.
  • The clinical features, diagnosis and EGFR flourescence in situ hybridization (FISH) study are presented.
  • The pathology revealed a malignant tumor composed of squamous cell carcinoma, adenocarcinoma and SNEC components.
  • CONCLUSION: A colliding tumor of squamous cell, adenocarcinoma and neuroendocrine carcinoma in maxillary sinus was aggressive in behavior and the treatment response was poor due to the complexity of tumor.
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Fatal Outcome. Female. Follow-Up Studies. Humans. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Middle Aged

  • Genetic Alliance. consumer health - Sinus cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Otol Rhinol Laryngol. 2001 Jan;110(1):76-82 [11201814.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):717-23 [17974556.001]
  • [Cites] Mod Pathol. 2002 Mar;15(3):264-78 [11904342.001]
  • [Cites] Pathol Int. 2003 Jan;53(1):58-65 [12558872.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1980-7 [12743152.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):77-85 [14701768.001]
  • [Cites] Histopathology. 2004 Jun;44(6):570-9 [15186272.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Ear Nose Throat J. 2004 Aug;83(8):530, 532 [15487631.001]
  • [Cites] Otolaryngol Head Neck Surg. 1982 Jul-Aug;90(4):516-7 [6294577.001]
  • [Cites] Otolaryngol Head Neck Surg. 1986 Jul;95(1):99-103 [3033580.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 1991;53(4):210-9 [1653928.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Laryngol Otol. 2006 Apr;120(4):289-97 [16526967.001]
  • [Cites] Virchows Arch. 2006 Jul;449(1):135-6 [16570181.001]
  • [Cites] Acta Otorhinolaryngol Belg. 2001;55(3):251-7 [11685964.001]
  • (PMID = 20961443.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2984401
  •  go-up   go-down


23. Bogazzi F, Russo D, Locci MT, Chifenti B, Ultimieri F, Raggi F, Cosci C, Sardella C, Costa A, Gasperi M, Bartalena L, Martino E: Apoptosis is reduced in the colonic mucosa of patients with acromegaly. Clin Endocrinol (Oxf); 2005 Dec;63(6):683-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GH and IGF-1 decrease apoptosis in several cell lines including human colonic adenocarcinoma, but it is unknown whether epithelial cells of colonic mucosa of patients with acromegaly have reduced apoptosis.
  • Apoptosis was inversely related to serum IGF-I (r = 0.771, P < 0.001) or GH (r = 0.404, P = 0.05) levels and less to the estimated duration of disease (r = 0.384, P = 0.07).
  • [MeSH-minor] Adult. Analysis of Variance. Blotting, Western / methods. Colonoscopy. Cross-Sectional Studies. Female. Growth Hormone / blood. Humans. In Situ Nick-End Labeling. Insulin-Like Growth Factor I / analysis. Linear Models. Male. Middle Aged. PPAR gamma / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acromegaly.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343104.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / PPAR gamma; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


24. Zhao XL, Cheng SX, Kong XD: [Expression and significance of P16INK4A and PTEN in high-risk human papillomavirus-related cervical cancer]. Ai Zheng; 2007 May;26(5):480-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expression of P16INK4A and PTEN in 30 specimens of normal cervical tissues, 11 specimens of cancer in situ (CIS), and 24 specimens of invasive cervical carcinoma (ICC) was detected by SP immunohistochemistry; 13 types of HR-HPV DNA in these cases were detected by Hybrid Capture 2 (HC-2) assay.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / virology. Adult. Aged. Carcinoma in Situ / metabolism. Carcinoma in Situ / virology. Cervix Uteri / metabolism. Cervix Uteri / virology. DNA, Viral / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Papillomaviridae. Young Adult

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672936.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


25. Platell C: Transanal endoscopic microsurgery. ANZ J Surg; 2009 Apr;79(4):275-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology indicated 128 adenomas, 52 carcinomas in situ, and 52 adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Carcinoma in Situ / surgery. Colonoscopy / statistics & numerical data. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432714.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


26. Yaman B, Nart D, Yilmaz F, Coker A, Zeytunlu M, Kilic M: Biliary intraductal papillary mucinous neoplasia: three case reports. Virchows Arch; 2009 May;454(5):589-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • b-IPMN is classified as adenoma, borderline tumor, carcinoma in situ, and carcinoma, from benign to malignant.
  • Case 2 was diagnosed as carcinoma in situ.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Papillary / pathology. Cholangiocarcinoma / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Disease-Free Survival. Hepatitis B / complications. Hepatitis B / surgery. Humans. Immunoenzyme Techniques. Liver Cirrhosis / surgery. Liver Cirrhosis / virology. Liver Transplantation. Male. Middle Aged. Mucin 5AC / metabolism. Mucin-1 / metabolism. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 2007 Aug;39(4):413-8 [17676483.001]
  • [Cites] Histol Histopathol. 2008 Jan;23 (1):41-50 [17952856.001]
  • [Cites] Hum Pathol. 2003 Sep;34(9):902-10 [14562286.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):794-9 [16088402.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):327-38 [15104295.001]
  • [Cites] Ann Surg. 1998 Jan;227(1):63-9 [9445112.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):350-8 [16360234.001]
  • [Cites] Pancreas. 2007 Nov;35(4):348-52 [18090241.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):651-8 [11584359.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):249-50 [16360969.001]
  • [Cites] Lab Invest. 2004 May;84(5):629-38 [15048136.001]
  • [Cites] Cancer. 1989 Apr 15;63(8):1562-6 [2538218.001]
  • [Cites] Ann Diagn Pathol. 2007 Feb;11(1):34-8 [17240305.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1570-2 [17922173.001]
  • [Cites] Hepatology. 2006 Nov;44(5):1333-43 [17058219.001]
  • [Cites] Endoscopy. 2000 May;32(5):389-93 [10817178.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1243-54 [16741522.001]
  • [Cites] J Pathol. 2002 Jun;197(2):201-10 [12015744.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):45-54 [10227724.001]
  • [Cites] J Surg Oncol. 1998 Nov;69(3):162-7 [9846503.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):783-93 [14770435.001]
  • (PMID = 19347361.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1
  •  go-up   go-down


27. Coffey JC, Wang JH, Bouchier-Hayes D, Cotter TG, Redmond HP: The targeting of phosphoinositide-3 kinase attenuates pulmonary metastatic tumor growth following laparotomy. Ann Surg; 2006 Feb;243(2):250-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Balb/c mice underwent a tail vein injection of 1x10 metastatic murine mammary adenocarcinoma 4T1 cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Chromones / pharmacology. Enzyme Inhibitors / pharmacology. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Morpholines / pharmacology. Neoplasm Recurrence, Local / prevention & control. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / pathology. Neoplasms, Experimental / surgery. Phosphatidylinositol 3-Kinases / antagonists & inhibitors
  • [MeSH-minor] Animals. Apoptosis. Blotting, Western. Cell Division. In Situ Nick-End Labeling. Laparotomy. Mice. Mice, Inbred BALB C. Neoplasm Metastasis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(8):1311-7 [10604727.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 16;92(4):347-8 [10675389.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):880-6 [10741711.001]
  • [Cites] Surg Endosc. 2000 May;14(5):490-4 [10858479.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):371-5 [11260101.001]
  • [Cites] J Surg Res. 2001 Jun 1;98(1):27-32 [11368534.001]
  • [Cites] Br J Cancer. 2001 Jul 20;85(2):273-8 [11461089.001]
  • [Cites] Br J Cancer. 2001 Aug 17;85(4):490-2 [11506484.001]
  • [Cites] Oncogene. 2001 Sep 13;20(41):5799-809 [11593385.001]
  • [Cites] Trends Mol Med. 2001 Oct;7(10):455-62 [11597520.001]
  • [Cites] J Surg Res. 2001 Dec;101(2):111-9 [11735264.001]
  • [Cites] J Clin Invest. 2002 Jan;109(1):141-9 [11781359.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(3):965-77 [11784871.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):319-27 [11803475.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1087-92 [11861387.001]
  • [Cites] Science. 2002 May 31;296(5573):1655-7 [12040186.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4929-37 [12208743.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Oncogene. 2003 Jun 26;22(26):4092-101 [12821943.001]
  • [Cites] Lancet. 2003 Aug 16;362(9383):502-3 [12932377.001]
  • [Cites] Lancet. 2003 Aug 16;362(9383):527-33 [12932384.001]
  • [Cites] Cancer Sci. 2003 Dec;94(12):1066-73 [14662022.001]
  • [Cites] Lancet Oncol. 2003 Dec;4(12):760-8 [14662433.001]
  • [Cites] Cancer. 1980 Mar 15;45(6):1498-506 [6153570.001]
  • [Cites] N Engl J Med. 1986 Dec 25;315(26):1650-9 [3537791.001]
  • [Cites] J Surg Oncol. 1994 Jul;56(3):178-84 [8028350.001]
  • [Cites] Cell. 1994 Oct 21;79(2):315-28 [7525077.001]
  • [Cites] Science. 1995 Apr 7;268(5207):100-2 [7701328.001]
  • [Cites] Nat Med. 1995 Feb;1(2):149-53 [7585012.001]
  • [Cites] Lancet. 1995 Dec 9;346(8989):1506-7 [7491042.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Br J Surg. 1997 Mar;84(3):358-61 [9117307.001]
  • [Cites] Cell. 1997 Oct 17;91(2):231-41 [9346240.001]
  • [Cites] J Clin Invest. 1998 Mar 1;101(5):1055-63 [9486976.001]
  • [Cites] Arch Surg. 1998 Apr;133(4):383-9 [9565118.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):564-9 [9593237.001]
  • [Cites] Surgery. 1998 Sep;124(3):516-25 [9736904.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1439-42 [9782033.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):99-102 [9916799.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1392-8 [10188881.001]
  • [Cites] Br J Surg. 1999 Sep;86(9):1180-4 [10504374.001]
  • [Cites] Ann Thorac Surg. 2005 Mar;79(3):990-5; discussion 990-5 [15734421.001]
  • [Cites] J Biol Chem. 2005 Jun 3;280(22):20968-77 [15741161.001]
  • (PMID = 16432359.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromones; 0 / Enzyme Inhibitors; 0 / Morpholines; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  • [Other-IDs] NLM/ PMC1448916
  •  go-up   go-down


28. Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H: The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res; 2009 May 15;69(10):4270-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, no approved anti-HER2/neu therapy is available for the majority of breast cancer patients, who express HER2/neu at low levels (with scores of 1+ or 2+/fluorescence in situ hybridization-negative).
  • [MeSH-minor] Adenocarcinoma / pathology. Antineoplastic Agents / toxicity. Cecal Neoplasms / pathology. Cell Line, Tumor. Cell Survival / drug effects. Female. Gene Expression Profiling. Humans. Ileal Neoplasms / pathology. Leukocytes, Mononuclear / cytology. Leukocytes, Mononuclear / drug effects. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19435924.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / ertumaxomab; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


29. Bozzetti C, Tiseo M, Lagrasta C, Nizzoli R, Guazzi A, Graiani G, Rindi G, Ardizzoni A: Is cytology reliable for epidermal growth factor receptor gene evaluation in non-small cell lung cancer? J Thorac Oncol; 2010 Apr;5(4):551-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Cytologic and matched histologic samples from 33 primary non-small cell lung cancers were analyzed by fluorescence in situ hybridization (FISH) for epidermal growth factor receptor gene.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / pathology. Gene Dosage. In Situ Hybridization, Fluorescence. Lung Neoplasms / pathology. Receptor, Epidermal Growth Factor / genetics


30. Jouret-Mourin A, Sempoux C, Duc KH, Geboes K: Usefulness of histopathological markers in diagnosing Barrett's intraepithelial neoplasia (dysplasia). Acta Gastroenterol Belg; 2009 Oct-Dec;72(4):425-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of histopathological markers in diagnosing Barrett's intraepithelial neoplasia (dysplasia).
  • The incidence of oesophageal adenocarcinoma has significantly increased in Europe over the last 30 years.
  • The progression from normal mucosa to adenocarcinoma has been associated with genetic and morphological traits regrouped under the term "intraepithelial neoplasia" (IEN) according to the Vienna classification.
  • Discrepancies between high grade IEN and adenocarcinoma can be minimized by using the Vienna classification, which groups both of these lesions under the "stage IV".
  • Erroneous and overstated diagnosis of low grade IEN induces an unnecessary follow-up of patients with obvious psychological and economic consequences.
  • P504 S has been studied in Barrett's disease and might be a novel tool.
  • [MeSH-major] Barrett Esophagus / pathology. Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. Esophageal Neoplasms / pathology
  • [MeSH-minor] Disease Progression. Humans. Ki-67 Antigen / analysis. Racemases and Epimerases / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20163037.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Number-of-references] 42
  •  go-up   go-down


31. Chiang KC, Hsu JT, Chen HY, Jwo SC, Hwang TL, Jan YY, Yeh CN: Multifocal intraductal papillary mucinous neoplasm of the pancreas--a case report. World J Gastroenterol; 2009 Feb 7;15(5):628-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been most commonly described in 60 to 70 years old males, and represents a relatively "new" but increasingly recognized disease.
  • Here we present a 72-year-old male diagnosed with IPMN (carcinoma in situ) in the pancreatic head and a branch duct type IPMN (duct atypia) in the pancreatic body and tail.
  • A three-year disease-free survival has been observed so far.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology
  • [MeSH-minor] Aged. Carcinoma in Situ / pathology. Carcinoma in Situ / radiography. Carcinoma in Situ / ultrasonography. Endoscopy. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed. Treatment Outcome. Weight Loss

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1999 Oct;178(4):269-74 [10587182.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Int J Pancreatol. 2000 Jun;27(3):181-93 [10952400.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Pancreas. 2001 May;22(4):370-7 [11345137.001]
  • [Cites] Am J Surg. 2001 Aug;182(2):188-91 [11574095.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):34-43 [11781278.001]
  • [Cites] Gastrointest Endosc. 2002 May;55(6):701-14 [11979253.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Radiology. 1987 Oct;165(1):51-5 [3306789.001]
  • [Cites] Hum Pathol. 1989 Aug;20(8):806-7 [2744753.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1329-35 [2548703.001]
  • [Cites] Pancreas. 1991 Jan;6(1):15-22 [1994377.001]
  • [Cites] Gastrointest Endosc. 1991 Mar-Apr;37(2):133-8 [1851707.001]
  • [Cites] Gastrointest Endosc. 1991 Mar-Apr;37(2):199-201 [1851710.001]
  • [Cites] Pancreas. 1992;7(1):114-7 [1557339.001]
  • [Cites] Am J Gastroenterol. 1992 May;87(5):634-8 [1317671.001]
  • [Cites] Gastrointest Endosc Clin N Am. 1995 Jan;5(1):237-58 [7728346.001]
  • [Cites] Am J Surg. 1996 Apr;171(4):427-31 [8604836.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1909-18 [8964418.001]
  • [Cites] Ann Surg. 1997 Jun;225(6):637-44; discussion 644-6 [9230804.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):42-9 [9468422.001]
  • [Cites] Am J Surg. 1998 May;175(5):426-32 [9600293.001]
  • [Cites] Gastrointest Endosc. 1998 Nov;48(5):556-9 [9831858.001]
  • [Cites] Ann Surg. 1998 Nov;228(5):685-91 [9833807.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1973-80 [9951850.001]
  • [Cites] Eur J Surg. 1999 Mar;165(3):223-9 [10231655.001]
  • [Cites] Arch Surg. 1999 Oct;134(10):1131-6 [10522860.001]
  • [Cites] Ann Surg. 1965 Jun;161:845-63 [14295937.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Apr;4(4):460-8 [16616351.001]
  • [Cites] Int J Pancreatol. 1999 Oct;26(2):93-8 [10597405.001]
  • (PMID = 19195068.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2653357
  •  go-up   go-down


32. Illemann M, Bird N, Majeed A, Sehested M, Laerum OD, Lund LR, Danø K, Nielsen BS: MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res; 2006 May;4(5):293-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases.
  • To test whether MMP-9 is also induced in tumor edge macrophages in metastases from colorectal adenocarcinomas, we have compared the expression pattern of MMP-9 in primary colorectal adenocarcinomas (n = 15) with that in liver metastases (n = 15) and local lymph node metastases (n = 7) from the same patients by in situ hybridization and immunohistochemistry.
  • In all the colorectal adenocarcinomas, the expression of MMP-9 mRNA and immunoreactivity in macrophages was located at the invasive front.
  • [MeSH-major] Adenocarcinoma / enzymology. Colorectal Neoplasms / enzymology. Matrix Metalloproteinase 9 / biosynthesis
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies / chemistry. Female. Humans. Immunoenzyme Techniques / methods. In Situ Hybridization / methods. Liver Neoplasms / enzymology. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. RNA, Messenger / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16687484.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / RNA, Messenger; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


33. Piris A, Scopsi L, Clemente C, Cetti Serbelloni F, Mihm MC Jr, Hoang MP: Epidermal growth factor receptor gene status by fluorescence in situ hybridization in malignant, atypical, and benign hidradenomas. Am J Dermatopathol; 2010 Aug;32(6):586-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor gene status by fluorescence in situ hybridization in malignant, atypical, and benign hidradenomas.
  • We have previously reported EGFR protein overexpression in malignant, atypical, and benign hidradenomas and would like to further evaluate their gene status by fluorescence in situ hybridization.
  • METHODS: Fluorescence in situ hybridization by 2-color probe Vysis LSI EGFR SpectrumOrange/CEP 7 SpectrumGreen Probe (Abbott Molecular) and EGFR immunostain (H11, Dakocytomation) were performed in 15 malignant, 15 atypical, and 7 benign hidradenomas.
  • [MeSH-major] Acrospiroma / pathology. Adenocarcinoma / secondary. Gene Expression Regulation, Neoplastic. Receptor, Epidermal Growth Factor / genetics. Sweat Gland Neoplasms / genetics. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Proliferation. Chromosome Aberrations. Gene Amplification. Humans. In Situ Hybridization, Fluorescence / methods. Lymph Nodes / pathology. Trisomy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534988.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


34. Conill C, Vargas M, Valduvieco I, Fernández PL, Cardesa A, Capurro S: Metastasis to the nasal cavity from primary rectal adenocarcinoma. Clin Transl Oncol; 2009 Feb;11(2):117-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis to the nasal cavity from primary rectal adenocarcinoma.
  • The lesion had an immunohistochemical (positivity for cytokeratin 20, negativity for cytokeratin 7, overexpression of p53) and in situ hybridisation profile (neither lesions showed deletion for p53) consistent with metastasis from the earlier rectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Nasal Cavity / pathology. Paranasal Sinus Neoplasms / secondary. Rectal Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Vestn Otorinolaringol. 1989 Mar-Apr;(2):85-6 [2728188.001]
  • [Cites] J Laryngol Otol. 1973 Jun;87(6):603-9 [4718451.001]
  • [Cites] J Laryngol Otol. 1985 May;99(5):459-62 [3998631.001]
  • [Cites] Int J Clin Oncol. 2006 Feb;11(1):64-5 [16508732.001]
  • [Cites] J Fac Radiol. 1959 Jul;10 :151-5 [24546097.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2002 Sep-Oct;64(5):364-7 [12417782.001]
  • (PMID = 19211379.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


35. Sakamoto H, Shimizu J, Horio Y, Ueda R, Takahashi T, Mitsudomi T, Yatabe Y: Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol; 2007 Jul;212(3):287-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas.
  • In the resected lung, additional small lesions are occasionally found incidentally, and include the full spectrum of preinvasive to invasive lesions under the current putative schema of the sequential development of lung cancer.
  • In this study, we examined EGFR and KRAS gene mutations in 119 synchronous pulmonary lesions, including 40 precursor lesions (atypical adenomatous hyperplasia, AAH), 26 carcinomas in situ (non-mucinous bronchioloalveolar carcinoma, BAC), 14 minimally invasive adenocarcinomas, 34 overt invasive adenocarcinomas, and five of other subtypes of cancer.
  • Although the mutually exclusive nature of KRAS and EGFR gene mutations was maintained even in preinvasive lesions, the incidences of the lesions along the putative progression schema were quite different.
  • The KRAS gene was mutated in 33% of AAH, 12% of carcinomas in situ, 8% of minimally invasive adenocarcinomas and 0% of well-differentiated adenocarcinomas, whereas the frequencies of EGFR mutation did not fluctuate greatly, at 25%, 51%, 36%, 86% and 67%, respectively.
  • These results are consistent with the findings of a published gene-targeted mouse model; the mice expressing oncogenic KRAS developed AAH but not invasive adenocarcinoma, whereas a spectrum of preinvasive to invasive adenocarcinomas was observed in the mice expressing mutant EGFR.
  • [MeSH-major] Adenocarcinoma / genetics. Lung Neoplasms / genetics. Mutation. Neoplasms, Multiple Primary / genetics. Precancerous Conditions / genetics. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics
  • [MeSH-minor] DNA Mutational Analysis. Disease Progression. Humans. Hyperplasia / genetics. Smoking / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 17534846.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


36. Ishikawa S, Nakagawa T, Miyahara R, Kawano Y, Takenaka K, Yanagihara K, Otake Y, Katakura H, Wada H, Tanaka F: Expression of MDA-7/IL-24 and its clinical significance in resected non-small cell lung cancer. Clin Cancer Res; 2005 Feb 1;11(3):1198-202
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was no significant difference in tumor angiogenesis or proliferative activity according to MDA-7/IL-24 status, but MDA-7/IL-24-high adenocarcinoma showed a significantly higher incidence of apoptotic tumor cell death than MDA-7/IL-24-low adenocarcinoma.
  • Subset analyses showed that positive MDA-7/IL-24 expression was a significant factor to predict a favorable prognosis in adenocarcinoma (P = 0.033), which was confirmed by a multivariate analysis; there was no difference in the prognosis according to MDA-7/IL-24 status in squamous cell carcinoma.
  • CONCLUSIONS: MDA-7/IL-24 status was a significant prognostic factor in lung adenocarcinoma, not in lung squamous cell carcinoma.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Apoptosis. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Genes, Tumor Suppressor. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709189.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukins; 0 / interleukin-24
  •  go-up   go-down


37. Pedersen ME, Rahr HB, Fenger C, Qvist N: Adenocarcinoma arising from the rectal stump eleven years after excision of an ileal J-pouch in a patient with ulcerative colitis: report of a case. Dis Colon Rectum; 2008 Jul;51(7):1146-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma arising from the rectal stump eleven years after excision of an ileal J-pouch in a patient with ulcerative colitis: report of a case.
  • Adenocarcinomas in relation to the ileal J-pouch after restorative proctocolectomy for ulcerative colitis have been recently reported with increasing frequency.
  • All previously reported cases have occurred in patients with their ileal pouch in situ.
  • We report a case of adenocarcinoma in the anal canal 11 years after removal of a failed ileal J-pouch.
  • [MeSH-major] Adenocarcinoma, Mucinous / etiology. Colitis, Ulcerative / surgery. Colonic Pouches / pathology. Rectal Neoplasms / etiology
  • [MeSH-minor] Anastomosis, Surgical. Biopsy. Diagnosis, Differential. Fatal Outcome. Follow-Up Studies. Humans. Ileostomy. Male. Middle Aged. Proctocolectomy, Restorative / methods. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437493.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Pettaway CA, Song R, Wang X, Sanchez-Ortiz R, Spiess PE, Strom S, Troncoso P: The ratio of matrix metalloproteinase to E-cadherin expression: a pilot study to assess mRNA and protein expression among African American prostate cancer patients. Prostate; 2008 Sep 15;68(13):1467-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A colorimetric mRNA in situ hybridization (ISH) assay was performed using biotinylated anti-sense oligonucleotide probes for MMP 2 and 9, as well as for E-cadherin gene transcripts.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Urology. 2001 Oct;58(4):614-8 [11597555.001]
  • [Cites] Metabolism. 2001 Oct;50(10):1242-7 [11586501.001]
  • [Cites] J Natl Cancer Inst. 2003 May 7;95(9):661-8 [12734317.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2185-94 [12796385.001]
  • [Cites] Biostatistics. 2003 Oct;4(4):523-38 [14557109.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 2):S6-9; discussion S10 [14610404.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8511-5 [14679018.001]
  • [Cites] Prostate. 2004 Sep 1;60(4):343-51 [15264247.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Am J Surg Pathol. 1989 Jan;13(1):21-7 [2909195.001]
  • [Cites] J Natl Med Assoc. 1990 Nov;82(11):782-8 [2258952.001]
  • [Cites] Lancet. 1992 Apr 11;339(8798):887-9 [1348296.001]
  • [Cites] Prostate Suppl. 1992;4:129-38 [1574453.001]
  • [Cites] J Histochem Cytochem. 1993 Apr;41(4):499-506 [8095509.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3929-33 [7518346.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1937-40 [7728763.001]
  • [Cites] J Urol. 1995 Nov;154(5):1808-12 [7563353.001]
  • [Cites] Pathol Res Pract. 1995 Sep;191(9):838-41 [8606862.001]
  • [Cites] Oncol Res. 1996;8(2):69-75 [8859777.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1020-2 [9067262.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1571-82 [9137084.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3189-93 [9242448.001]
  • [Cites] Prostate. 1997 Sep 15;33(1):9-12 [9294620.001]
  • [Cites] J Urol. 1998 Aug;160(2):437-42 [9679893.001]
  • [Cites] Clin Cancer Res. 1996 Sep;2(9):1627-36 [9816342.001]
  • [Cites] Prostate. 1998 Dec 1;37(4):230-5 [9831219.001]
  • [Cites] Urology. 1999 Apr;53(4):707-13 [10197845.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):783-9 [10213213.001]
  • [Cites] J Urol. 1999 Aug;162(2):394-7 [10411045.001]
  • [Cites] Urology. 1999 Jul;54(1):178-82 [10414748.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3552-6 [10446959.001]
  • [Cites] Lancet. 1999 Sep 18;354(9183):975-8 [10501358.001]
  • [Cites] Prostate. 2005 Feb 15;62(3):243-52 [15389726.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):75-82 [16736511.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):901-5 [10548319.001]
  • [Cites] Prostate. 2000 Jan;42(1):18-25 [10579795.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1107-10 [10613344.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):2104-19 [10815938.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2295-308 [10873080.001]
  • [Cites] J Natl Cancer Inst. 2001 Mar 7;93(5):388-95 [11238701.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1255-9 [11245414.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):943-7 [11535545.001]
  • [Cites] J Natl Cancer Inst. 2003 May 7;95(9):634-5 [12734304.001]
  • (PMID = 18618693.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090270-01; United States / NCI NIH HHS / CA / P50 CA090270; United States / NCI NIH HHS / CA / CA90270; United States / NCI NIH HHS / CA / P50 CA090270-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / RNA, Messenger; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ NIHMS57053; NLM/ PMC2574568
  •  go-up   go-down


39. Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR: Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res; 2009 Nov 1;69(21):8341-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.
  • In a subset of lung adenocarcinomas, the epidermal growth factor receptor (EGFR) is activated by kinase domain mutations and/or gene amplification, but the interaction between the two types of abnormalities is complex and unclear.
  • For this study, we selected 99 consecutive never-smoking women of East Asian origin with lung adenocarcinomas that were characterized by histologic subtype.
  • We analyzed EGFR mutations by PCR-capillary sequencing, EGFR copy number abnormalities by fluorescence and chromogenic in situ hybridization and quantitative PCR, and EGFR expression by immunohistochemistry with both specific antibodies against exon 19 deletion-mutated EGFR and total EGFR.
  • We compared molecular and clinicopathologic features with disease-free survival.
  • Lung adenocarcinomas with EGFR amplification had significantly more EGFR exon 19 deletion mutations than adenocarcinomas with disomy, and low and high polysomy (100% versus 54%, P = 0.009).
  • Patients with EGFR amplification had a significantly worse outcome in univariate analysis (median disease-free survival, 16 versus 31 months, P = 0.01) and when adjusted for stage (P = 0.027).
  • Lung adenocarcinomas with EGFR amplification have a unique association with exon 19 deletion mutations and show distinct clinicopathologic features associated with a significantly worsened prognosis.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44 [16467097.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):3023-8 [19366827.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):485-95 [16730237.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):169-81 [17318210.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2046-53 [17332333.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2248-55 [17538169.001]
  • [Cites] Mod Pathol. 2007 Oct;20(10):1028-35 [17673923.001]
  • [Cites] J Thorac Oncol. 2008 Apr;3(4):340-7 [18379350.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2106-11 [18381415.001]
  • [Cites] J Mol Diagn. 2008 May;10(3):242-8 [18403609.001]
  • [Cites] Am J Surg Pathol. 2008 Jun;32(6):810-27 [18391747.001]
  • [Cites] N Engl J Med. 2008 Sep 25;359(13):1367-80 [18815398.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8195-203 [15623594.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):226-35 [15665299.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1167-73 [15709185.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94 [16106023.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6838-45 [15998906.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6829-37 [15998907.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):751-8 [16467085.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Aug;1(3):192-200 [19138956.001]
  • [Cites] PLoS One. 2009;4(2):e4576 [19238210.001]
  • [Cites] Am J Clin Pathol. 2006 Jun;125(6):860-5 [16690485.001]
  • (PMID = 19826035.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA090578; United States / NCI NIH HHS / CA / CA092824; United States / NCI NIH HHS / CA / CA074386; United States / NCI NIH HHS / CA / CA090578-01A10003; United States / NCI NIH HHS / CA / P50 CA090578; United States / NCI NIH HHS / CA / R0I CA114465; United States / NCI NIH HHS / CA / R01 CA114465; United States / NCI NIH HHS / CA / P20 CA090578-01A10003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS143923; NLM/ PMC2783286
  •  go-up   go-down


40. Maeda D, Takazawa Y, Ota S, Takeuchi Y, Seta A, Nakagawa S, Yano T, Taketani Y, Fukayama M: Bilateral microscopic adenocarcinoma of the fallopian tubes detected by an endometrial cytologic smear. Int J Gynecol Pathol; 2010 May;29(3):273-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral microscopic adenocarcinoma of the fallopian tubes detected by an endometrial cytologic smear.
  • Primary adenocarcinoma of the fallopian tube is an uncommon female genital tract tumor.
  • In situ or minimally invasive tubal cancer often poses a diagnostic challenge because of the absence of specific clinical and radiological findings.
  • During the clinical diagnosis of endometrial cancer, she underwent bilateral salpingo-oophorectomy, total hysterectomy, and partial omentectomy.
  • In toto sectioning of the fallopian tubes and their fimbriated ends revealed minute foci of serous adenocarcinoma in the left tubal mucosa and right fimbria.
  • In situ adenocarcinoma components were present in both lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20407329.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Gozzi G, Martinoli C, Conti GM, Ganzetti A, Bodini M, Fiorentino C, Marini UP, Santini D, Bacigalupo L: Screening mammography interpretation test: more frequent mistakes. Radiol Med; 2005 Mar;109(3):268-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As regards the 23 most frequently misread cases, these were 10/32 (31.25%) mammograms positive for malignancy and 13/128 (10.15%) negative mammograms or mammograms showing benign disease.
  • The 10 malignancies included 7 infiltrating ductal carcinomas, 1 infiltrating cribriform carcinoma, 1 infiltrating tubular carcinoma, and 1 carcinoma in situ.
  • The 13 cases of benign disease--as established by histology or long-term follow-up--mistaken for malignancies by the test participants were fibrocystic breast disease in 5 cases, surgical scar in 1 case, ABBI scar in 1 case, radial scar in 2 cases, microcalcifications that had remained stable for years in 2 cases, focal sclero-adenosis in 1 case and sclero-elastosis in 1 case.
  • CONCLUSIONS: The errors were due to microcalcifications, benign disease simulating a neoplasm, overlapping tissue, visibility of a lesion in one projection only, lesion site in relation to the corpus mammae, missed areas of asymmetry.
  • Attention must be paid to these signs of focal breast disease since, if correctly evaluated, they enable the early diagnosis of low-grade carcinomas that frequently carry a favourable prognosis.
  • [MeSH-minor] Adenocarcinoma / radiography. Breast Diseases / surgery. Calcinosis / radiography. Carcinoma in Situ / radiography. Carcinoma, Ductal, Breast / radiography. Cicatrix / surgery. False Negative Reactions. False Positive Reactions. Female. Fibrocystic Breast Disease / radiography. Follow-Up Studies. Humans. Observer Variation


42. Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C, Izbicki JR, Sauter G: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol; 2009 Jun;40(6):769-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address the potential applicability of trastuzumab in gastric cancer, tissue microarray sections of 166 gastric adenocarcinomas and 69 lymph node metastases were analyzed for Her-2 overexpression and amplification using Food and Drug Administration-approved reagents for immunohistochemistry and fluorescence in situ hybridization.
  • HER-2 amplification was seen in 27 (16%) of 166 gastric adenocarcinomas.
  • The high level of HER-2 amplification in combination with the homogeneity of its expression in primary and metastatic tumors argues for a possible therapeutic utility of trastuzumab in HER-2-amplified gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antigens, Neoplasm / genetics. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Lymphatic Metastasis. Male. Middle Aged. Receptor, ErbB-2 / immunology. Tissue Array Analysis. Trastuzumab

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2011 Jun;42(6):909-10; author reply 910-1 [21571126.001]
  • [CommentIn] Hum Pathol. 2010 Feb;41(2):304-5; author reply 305-6 [19914678.001]
  • (PMID = 19269014.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; P188ANX8CK / Trastuzumab
  •  go-up   go-down


43. Li Y, Wang J, Zhu G, Zhang X, Zhai H, Zhang W, Wang W, Huang G: Detection of parvovirus B19 nucleic acids and expression of viral VP1/VP2 antigen in human colon carcinoma. Am J Gastroenterol; 2007 Jul;102(7):1489-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 119 paraffin-embedded specimens of colon polyps, adenocarcinomas, carcinoma-adjacent tissues, and normal controls were processed for nested polymerase chain reaction (PCR), in situ hybridization (ISH), immunohistochemistry (IHC), and laser capture micro dissection detection of B19 DNA and protein.
  • RESULTS: B19 DNA was detected in 94.6% (35/37) of colon adenocarcinomas, 67.6% (25/37) of adjacent noncancerous tissues, 85.6% (30/35) of polyps, and 60.0% (6/10) of normal controls by nested PCR, respectively.
  • ISH detected B19 DNA in 81.1% (30/37) of colon adenocarcinomas, 43.2% (16/37) of adjacent noncancerous tissues, 74.3% (26/35) of polyps, and 50.0% (5/10) of normal controls, respectively.
  • B19 protein VP1/VP2 was found in 78.4% (29/37), 32.4% (12/37), and 57.1% (20/35) of colon adenocarcinomas, tumor-adjacent tissues, and polyps, respectively, but not in normal colons (none of 10).
  • There were significant differences in nested PCR, ISH, and IHC between adenocarcinoma and non-neoplastic adjacent tissues, and between adenocarcinoma and normal controls.
  • CONCLUSIONS: Parvovirus B19 nucleic acids commonly exist in human colon tissues and VP1/VP2 antigen is preferentially located in colon polyps and adenocarcinomas lesions.
  • [MeSH-minor] Adult. Aged. Blotting, Western. Cyclooxygenase 2 / biosynthesis. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Parvoviridae Infections / metabolism. Parvoviridae Infections / pathology. Parvoviridae Infections / virology. Polymerase Chain Reaction. Retrospective Studies. Tumor Cells, Cultured. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459020.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Capsid Proteins; 0 / DNA, Viral; 0 / capsid protein VP1, parvovirus B19; 0 / capsid protein VP2, parvovirus B19; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


44. Li B, Li N, Cheng G, Sun X, Xu X, Shi J, Li L, Chen C: Correlation of the expression of telomerase RNA with risk factors for recurrence of sebaceous gland carcinoma. Graefes Arch Clin Exp Ophthalmol; 2006 Apr;244(4):480-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expression patterns of hTR and hTRT were detected by in situ hybridization (ISH) in paraffin-embedded samples of 55 eyelid sebaceous gland carcinoma, 12 chalazia, and four sebaceous adenoma.
  • CONCLUSIONS: Telomerase may play an important role in the carcinogenesis of sebaceous gland carcinoma, and expression of hTR and hTRT combined with other features of sebaceous gland carcinoma may be helpful for the diagnosis and evaluation of clinical prognosis.
  • [MeSH-major] Adenocarcinoma, Sebaceous / metabolism. Eyelid Neoplasms / metabolism. Neoplasm Recurrence, Local / metabolism. RNA, Untranslated / metabolism. Sebaceous Gland Neoplasms / metabolism. Telomerase / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Aged, 80 and over. Female. Gene Expression / physiology. Humans. Immunoenzyme Techniques. In Situ Hybridization. Ki-67 Antigen / metabolism. Male. Middle Aged. RNA. RNA, Long Noncoding. Risk Factors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):437-41 [9091645.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6476-81 [8692840.001]
  • [Cites] Zhonghua Yan Ke Za Zhi. 2002 Nov;38(11):684-7 [12487901.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] J Immunol. 1984 Oct;133(4):1710-5 [6206131.001]
  • [Cites] Hum Pathol. 1982 Feb;13(2):113-22 [7076199.001]
  • [Cites] Nature. 1989 Jan 26;337(6205):331-7 [2463488.001]
  • [Cites] Cell. 1989 Nov 3;59(3):521-9 [2805070.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):741-9 [10091748.001]
  • [Cites] Mod Pathol. 1994 Jan;7(1):37-43 [7909154.001]
  • [Cites] Hum Pathol. 1999 Nov;30(11):1302-8 [10571509.001]
  • [Cites] Int J Cancer. 1999 Aug 20;84(4):426-31 [10404098.001]
  • (PMID = 16133023.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / RNA, Long Noncoding; 0 / RNA, Untranslated; 0 / telomerase RNA; 63231-63-0 / RNA; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


45. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol; 2009 Sep 10;27(26):4247-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Patients with NSCLC were selected for genetic screening on the basis of two or more of the following characteristics: female sex, Asian ethnicity, never/light smoking history, and adenocarcinoma histology.
  • EML4-ALK was identified by using fluorescent in situ hybridization for ALK rearrangements and was confirmed by immunohistochemistry for ALK expression.
  • Eighteen of the 19 EML4-ALK tumors were adenocarcinomas, predominantly the signet ring cell subtype.
  • Among patients with metastatic disease, EML4-ALK positivity was associated with resistance to EGFR tyrosine kinase inhibitors (TKIs).


46. Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Iida K, Otsuki Y, Kobayashi H, Nakayama S, Miyazaki K: Expression of nuclear Notch3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes. Gynecol Oncol; 2010 Jun;117(3):409-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used dual-color fluorescence in situ hybridization (FISH) to analyze DNA copy number alterations in cervical cancer.
  • RESULTS: Immunohistochemical analysis revealed that Notch3 was significantly overexpressed in cervical squamous cell carcinomas compared with adenocarcinomas.
  • In contrast to normal cervical tissue and cervical intraepithelial neoplasms [CINs], squamous cell carcinomas demonstrated higher nuclear Notch3 immunoreactivity.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adult. Aged. Aged, 80 and over. Animals. Calcium-Binding Proteins / metabolism. Cell Line, Tumor. Cervical Intraepithelial Neoplasia / genetics. Cervical Intraepithelial Neoplasia / metabolism. DNA Copy Number Variations. DNA-Binding Proteins / metabolism. Female. Gene Knockdown Techniques. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence / methods. Intercellular Signaling Peptides and Proteins / metabolism. Membrane Proteins / metabolism. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Proto-Oncogene Proteins / metabolism. RNA, Small Interfering / administration & dosage. RNA, Small Interfering / genetics. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20359736.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / DNA-Binding Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / NOTCH3 protein, human; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0 / Receptors, Notch; 0 / pbx1 protein, human; 134324-36-0 / Serrate proteins
  •  go-up   go-down


47. Zeng X, Wu SF, Xu Q, Xiao Y, Liu TH: [Relationship between chromosome 8 alterations and Gleason score in prostatic adenocarcinoma]. Zhonghua Bing Li Xue Za Zhi; 2006 Sep;35(9):523-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between chromosome 8 alterations and Gleason score in prostatic adenocarcinoma].
  • OBJECTIVE: To study the gain of chromosome 8 and c-myc gene and lipoprotein lipase gene status in prostatic adenocarcinoma of Chinese patients, and to analyze the relationship between chromosome 8 alterations and Gleason score of prostatic cancer.
  • METHODS: Formalin-fixed, paraffin-embedded prostatic biopsy tissues from 34 Chinese patients with untreated prostatic adenocarcinoma were studied by three-color fluorescence in situ hybridization (FISH) using ProVysion(TM) probe kit.
  • CONCLUSIONS: Alterations in chromosome 8 are common in prostatic adenocarcinoma occurring in Chinese patients.
  • Our data suggest that chromosome 8 alterations may play some roles in the development and progression of prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Chromosome Aberrations. Chromosomes, Human, Pair 8 / genetics. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Gene Deletion. Gene Dosage. Humans. In Situ Hybridization, Fluorescence. Lipoprotein Lipase / genetics. Male. Middle Aged. Proto-Oncogene Proteins c-myc / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134545.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myc; EC 3.1.1.34 / Lipoprotein Lipase
  •  go-up   go-down


48. Fernández-Aguilar S, Simon P, Buxant F, Simonart T, Noël JC: Tubular carcinoma of the breast and associated intra-epithelial lesions: a comparative study with invasive low-grade ductal carcinomas. Virchows Arch; 2005 Oct;447(4):683-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular carcinoma of the breast and associated intra-epithelial lesions: a comparative study with invasive low-grade ductal carcinomas.
  • Ductal intra-epithelial lesions of the breast are associated with invasive neoplasms and comprise a large spectrum of histological patterns.
  • We have examined 23 cases of pure tubular carcinomas (TCs) of the breast and 53 cases of invasive ductal low-grade carcinomas to determine the relationship and distribution of intra-epithelial lesions, mainly of ductal in situ carcinoma type, but including also lobular intra-epithelial neoplasia (LIN) in both entities.
  • Eleven cases of TC showed flat epithelial atypia (FEA) (47.8%), and, in 14 and 6 cases, micropapillary and cribriform low-grade ductal carcinoma in situ (DCIS) were present (60.7 and 26.1%, respectively).
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2004 Apr;444(4):340-4 [14986131.001]
  • [Cites] Mol Pathol. 2001 Oct;54(5):300-6 [11577171.001]
  • [Cites] Am J Clin Pathol. 1997 May;107(5):561-6 [9128269.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1521-7 [9850178.001]
  • [Cites] Virchows Arch. 2001 Mar;438(3):221-7 [11315617.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Am J Surg Pathol. 1982 Jul;6(5):401-11 [6289683.001]
  • [Cites] Br J Surg. 2001 Jun;88(6):860-4 [11412259.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):140-54 [9504685.001]
  • [Cites] Virchows Arch. 1999 Oct;435(4):413-21 [10526005.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):728-39 [15491969.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1433-6 [10197608.001]
  • [Cites] Am J Clin Pathol. 1972 Sep;58(3):231-8 [4342376.001]
  • [Cites] Int J Surg Pathol. 2001 Jul;9(3):201-6 [11584316.001]
  • [Cites] Endocr Relat Cancer. 2001 Mar;8(1):47-61 [11350726.001]
  • [Cites] Hum Pathol. 2001 Feb;32(2):222-6 [11230710.001]
  • (PMID = 16091953.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


49. Meng ZL, Guo LN, Luo YF, Cao JL, Wan JW, Liu TH: [Role of HPV DNA detection and p16(INK4A) protein expression in diagnosis of endocervical adenocarcinoma]. Zhonghua Bing Li Xue Za Zhi; 2007 Dec;36(12):810-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of HPV DNA detection and p16(INK4A) protein expression in diagnosis of endocervical adenocarcinoma].
  • OBJECTIVES: To evaluate the significance of p16(INK4A) protein expression and positivity for HPV DNA in distinguishing between endocervical and endometrial adenocarcinoma.
  • METHODS: Expression of p16(INK4A) protein in 30 cases of endocervical adenocarcinoma and 10 cases of endometrial adenocarcinoma was assessed by immunohistochemistry.
  • In-situ hybridization for human papillomavirus (HPV) DNA was also performed in 20 cases of endocervical adenocarcinoma and 10 cases of endometrial adenocarcinoma.
  • RESULTS: The positive rate for p16(INK4A) in endocervical adenocarcinoma was 70% (21/30), as compared with 30% (3/10) in endometrial adenocarcinoma.
  • The tumor cells in endocervical adenocarcinoma showed diffuse and strong expression of p16(INK4A) protein with both cytoplasmic and nuclear staining.
  • In contrast, the endometrial adenocarcinoma cells showed patchy and weak expression of p16(INK4A).
  • On the other hand, HPV DNA (type 16 or 18) was detected by in-situ hybridization in 9 (45%) of the 20 cases of endocervical adenocarcinoma and none of the 10 cases of endometrial adenocarcinoma.
  • CONCLUSIONS: The expression of p16(INK4A) protein is significantly higher in endocervical adenocarcinoma than in endometrial adenocarcinoma.
  • This expression pattern can serve as a useful immunohistochemical marker in the differential diagnosis. p16(INK4A) protein immunohistochemistry appears to be more sensitive than HPV DNA testing in distinguishing between endocervical and endometrial adenocarcinoma, especially in biopsy or curettage specimens.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA, Viral / analysis. Gene Expression Regulation, Neoplastic. Human papillomavirus 16 / genetics. Human papillomavirus 18 / genetics. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / genetics. Endometrial Neoplasms / virology. Female. Humans. In Situ Hybridization

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18346352.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral
  •  go-up   go-down


50. McCluggage WG, Hurrell DP, Kennedy K: Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. Am J Surg Pathol; 2010 May;34(5):735-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases.
  • A variety of other neoplasms rarely metastasize to the cervix and, in most cases, the diagnosis is straightforward because of a combination of clinical and pathologic parameters, common features of metastatic carcinoma within the cervix including predominant involvement of the deep stroma, absence of surface involvement and of an in situ component, and prominent lymphovascular permeation.
  • We describe 6 cases of metastatic adenocarcinoma involving the cervix with superficial "mucosal" involvement mimicking primary cervical adenocarcinoma or adenocarcinoma in situ.
  • In 5 cases, the primary adenocarcinoma was in the ovary or peritoneum and was of serous (4 cases) or clear-cell (1 case) type.
  • In the other case, the primary neoplasm was in the pancreas and this was initially interpreted as a primary cervical adenocarcinoma.
  • It is important for the pathologist to be aware of the possibility of cervical mucosal metastasis to avoid an erroneous diagnosis of a primary cervical adenocarcinoma or adenocarcinoma in situ.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged


51. Götte K, Ganssmann S, Affolter A, Schäfer C, Riedel F, Arens N, Finger S, Hörmann K: Dual FISH analysis of benign and malignant tumors of the salivary glands and paranasal sinuses. Oncol Rep; 2005 Nov;14(5):1103-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined 58 of these tumors (14 adenoid cystic carcinomas, 9 adenocarcinomas, 5 cylindrical carcinomas, 11 pleomorphic adenomas, and 19 inverted papillomas) by dual fluorescence in situ hybridization (FISH) with centromere-specific probes on six chromosomes (3, 7, 9, 11, 17, and 18) for numerical changes.
  • In adenocarcinomas, monosomy of chromosome 17 and polysomy of chromosomes 7 and 11 were most frequent.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenoma / diagnosis. Adenoma / genetics. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / genetics. Chromosome Aberrations. Papilloma / diagnosis. Papilloma / genetics. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / genetics
  • [MeSH-minor] Diagnosis, Differential. Humans. In Situ Hybridization, Fluorescence. Salivary Gland Diseases / diagnosis. Salivary Gland Diseases / genetics

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211271.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


52. van Duin M, van Marion R, Vissers K, Watson JE, van Weerden WM, Schröder FH, Hop WC, van der Kwast TH, Collins C, van Dekken H: High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer; 2005 Dec;44(4):438-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, a detailed genomic analysis of 8q was performed of archival primary and metastatic prostatic adenocarcinomas (n = 22), and prostate cancer xenografts (n = 9), and cell lines (n = 3).
  • Quantitative RT-PCR of these 16 genes was performed in a series of 26 prostate specimens, including normal tissue (n = 5), fresh-frozen adenocarcinoma (n = 7), cancer xenograft (n = 9), and cancer cell line material (n = 2).
  • [MeSH-minor] Adenocarcinoma / pathology. Cell Line, Tumor. Chromosomes, Artificial, Bacterial. Genes, Neoplasm. Genetic Markers. Humans. In Situ Hybridization, Fluorescence. Male. Microdissection. Neoplasm Metastasis. Neoplasm Transplantation. Reverse Transcriptase Polymerase Chain Reaction. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetics Home Reference. consumer health - WASHC5 gene.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16130124.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 9007-49-2 / DNA
  •  go-up   go-down


53. Trimeche M, Ksiâa F, Ziadi S, Mestiri S, Hachana M, Gacem RB, Sriha B, Korbi S: Prevalence and characteristics of Epstein-Barr virus-associated gastric carcinomas in Tunisia. Eur J Gastroenterol Hepatol; 2009 Sep;21(9):1001-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Ninety-six nonselected GC cases (male/female ratio 1.7/1, mean age 60.9 years, range: 20-88 years) were evaluated for the presence of EBV by polymerase chain reaction as well as by in-situ hybridization for EBV-encoded small RNAs (EBERs) and immunohistochemistry for LMP-1 and EBNA-2 expression.
  • [MeSH-major] Adenocarcinoma / pathology. Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / isolation & purification. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19491698.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


54. Lima MA, Ferreira MV, Barros MA, Pardini MI, Ferrasi AC, Mota RM, Rabenhorst SH: Relationship between EBV infection and expression of cellular proteins c-Myc, Bcl-2, and Bax in gastric carcinomas. Diagn Mol Pathol; 2008 Jun;17(2):82-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: One hundred patients of gastric carcinoma, obtained from 2 hospitals in Fortaleza, Brazil were assessed for the presence of EBV by in situ hybridization, for the expression of Bcl-2, Bax, and c-Myc (nuclear and cytoplasmic staining) proteins by immunohistochemistry techniques, and for the apoptotic index.
  • [MeSH-major] Adenocarcinoma / metabolism. Epstein-Barr Virus Infections / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-myc / metabolism. Stomach Neoplasms / metabolism. bcl-2-Associated X Protein / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Biomarkers, Tumor / metabolism. Female. Gastrectomy. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Viral / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382371.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / Biomarkers, Tumor; 0 / Epstein-Barr virus encoded RNA 1; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Viral; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


55. Ikeda S, Takabe K, Inagaki M, Funakoshi N, Suzuki K: [Detection of ALK positive pulmonary adenocarcinoma using immunostaining]. Rinsho Byori; 2010 Jun;58(6):565-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of ALK positive pulmonary adenocarcinoma using immunostaining].
  • Resected lung adenocarcinoma samples from 88 nonsmoker cases were selected and screening was performed using ALK immunostaining in 24 cases that did not have the EGFR or k-ras mutation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Lung Neoplasms / diagnosis. Mutation. Oncogene Proteins, Fusion / analysis. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Chimerin Proteins / genetics. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20662267.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chimerin Proteins; 0 / EML4-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


56. Watanabe H, Okada G, Ohtsubo K, Yamaguchi Y, Mouri H, Motoo Y, Wakabayashi T, Sawabu N: Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas, and chronic pancreatitis. Pancreas; 2005 May;30(4):349-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesothelin mRNA expression was confirmed with in situ hybridization in all 4 resected primary PCa tumors and with RT-PCR in 18 of 20 PCa cell lines, whereas mesothelin protein expression was confirmed with immunohistochemistry in all 60 resected primary PCa tissues by Argani et al.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Papillary / diagnosis. Membrane Glycoproteins / genetics. Pancreatic Neoplasms / diagnosis. Pancreatitis, Chronic / diagnosis

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841046.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / RNA, Messenger; 0 / mesothelin
  •  go-up   go-down


57. Amirghofran Z, Monabati A, Gholijani N: Apoptosis in prostate cancer: bax correlation with stage. Int J Urol; 2005 Apr;12(4):340-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis. Prostatic Neoplasms / pathology. Proto-Oncogene Proteins c-bcl-2 / biosynthesis
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal. Biomarkers, Tumor / metabolism. Biopsy. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Ki-67 Antigen / biosynthesis. Ki-67 Antigen / immunology. Male. Middle Aged. Neoplasm Staging. Prognosis. bcl-2-Associated X Protein

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948719.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / BAX protein, human; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


58. De Braekeleer E, Meyer C, Douet-Guilbert N, Morel F, Le Bris MJ, Berthou C, Arnaud B, Marschalek R, Férec C, De Braekeleer M: Complex and cryptic chromosomal rearrangements involving the MLL gene in acute leukemia: a study of 7 patients and review of the literature. Blood Cells Mol Dis; 2010 Apr 15;44(4):268-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fluorescent in situ hybridization with a panel of probes coupled with long distance inverse-PCR was used to identify chromosomal rearrangements involving the MLL gene.
  • Should an abnormality be discovered, the analysis has to be completed by further molecular cytogenetic and genomic PCR methods in order to unravel the recombination mechanism.
  • [MeSH-minor] Acute Disease. Adenocarcinoma. Adult. Aged. Blast Crisis / genetics. Child, Preschool. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 11 / ultrastructure. Duodenal Neoplasms. Female. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence. Infant. Infant, Newborn. Leukemia, Monocytic, Acute / congenital. Leukemia, Monocytic, Acute / genetics. Leukemia, Myelomonocytic, Acute / genetics. Leukemia, Myelomonocytic, Chronic / pathology. Male. Mutagenesis, Insertional. Neoplasms, Second Primary / genetics. Oncogene Proteins, Fusion / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Prostatic Neoplasms. Sequence Deletion. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20206559.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 70
  •  go-up   go-down


59. Sidoruk AA, Novik VI, Urmancheeva AF: [Clinico-morphological diagnosis of adenocarcinoma in situ of the cervix uteri]. Vopr Onkol; 2009;55(6):733-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinico-morphological diagnosis of adenocarcinoma in situ of the cervix uteri].
  • Clinical and morphological investigation involved 57 patients with adenocarcinoma in situ of the cervix uteri (poorly-differentiated (precancerous) cell carcinoma in situ (PAIS)--30; adenocarcinoma in situ (AIS)--27).
  • Predictions for PAIS histotype were confirmed in 83%, cytological findings--78%; AIS--52% and 58%, respectively.
  • Accuracy for PAIS and AIS biopsy was 52% and 32%, respectively.
  • However, our procedure failed to detect malignant process in 17.5% (PAIS--6 cases and AIS--4) which was established by use of smears (Feulgen).
  • [MeSH-major] Adenocarcinoma / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Vaginal Smears


60. Chen L, Yang B: Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology. Cancer; 2008 Aug 25;114(4):236-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Reflex human papillomavirus (HPV) testing for atypical squamous cells of undetermined significance (ASC-US) has improved the sensitivity and specificity in detecting high-grade squamous dysplasia (cervical intraepithelial neoplasia [CIN]2+).
  • The most severe histopathologic diagnosis was recorded.
  • Histopathologic examination of the 64 HPV-positive AEC cases revealed 18 cases of endocervical adenocarcinoma in situ/adenocarcinoma (AIS+) and 22 cases of CIN2+.
  • Among 253 of the HPV-negative AEC women, AIS+ was found in only 3 cases and CIN2+ in 1 case.
  • Cervical AIS+ was found in 28% of the HPV-positive AEC patients and in only 0.9% of the HPV-negative patients (P<.0001).
  • When the significant glandular (AIS+) and squamous (CIN2+) lesions were combined, 62.5% of the lesions were detected in HPV-positive AEC cases compared with 1.6% in the HPV-negative AEC cases (P<.0001).
  • CONCLUSIONS: Because of a high sensitivity (91.0%) and high specificity (91.2%) in detecting significant cervical lesions, reflex HPV testing for cytologic diagnosis of AEC appears to be a useful ancillary tool in the selection of high-risk patients for colposcopy.
  • [MeSH-major] Cervix Uteri / pathology. DNA, Viral / analysis. Papanicolaou Test. Papillomaviridae / isolation & purification. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adult. Aged. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / pathology. Female. Follow-Up Studies. Humans. Middle Aged. Retrospective Studies. Sensitivity and Specificity


61. Kuuselo R, Simon R, Karhu R, Tennstedt P, Marx AH, Izbicki JR, Yekebas E, Sauter G, Kallioniemi A: 19q13 amplification is associated with high grade and stage in pancreatic cancer. Genes Chromosomes Cancer; 2010 Jun;49(6):569-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic cancer is a devastating disease with an extremely poor prognosis, and thus, there is a great need for better diagnostic and therapeutic tools.
  • We used fluorescence in situ hybridization on tissue microarrays containing 357 primary pancreatic tumors, 151 metastases, and 24 local recurrences as well as 120 cancer cell lines from various tissues to establish the frequency of the 19q13 amplification and to find potential correlations to clinical parameters including patient survival.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • [Cites] Genes Chromosomes Cancer. 2009 Apr;48(4):289-309 [19105235.001]
  • [Cites] PLoS Genet. 2008 May;4(5):e1000081 [18535672.001]
  • [Cites] Mod Pathol. 2009 Apr;22(4):499-507 [19151661.001]
  • [Cites] Cancer Biol Ther. 2008 Nov;7(11):1793-802 [18836286.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):787-94 [10980118.001]
  • [Cites] Cancer Lett. 2001 Jun 26;167(2):115-23 [11369131.001]
  • [Cites] Cytometry. 2001 Oct 1;45(2):83-6 [11590619.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1720-30 [12060609.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Dec;35(4):353-8 [12378529.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7157-61 [12499249.001]
  • [Cites] Breast Cancer Res Treat. 2003 Apr;78(3):337-45 [12755492.001]
  • [Cites] BMC Cancer. 2004 Feb 6;4:5 [15018632.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9067-72 [15199222.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4428-33 [15231651.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jul;84(14):5034-7 [3037531.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9 [1350088.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9267-71 [1409633.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):422-8 [8375927.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2156-60 [8134364.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1801-6 [8137295.001]
  • [Cites] Int J Cancer. 1995 Aug 22;64(4):280-5 [7657393.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Mar;87(1):55-62 [8646743.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2383-90 [9796969.001]
  • [Cites] Am J Clin Pathol. 1999 Jul;112(1 Suppl 1):S11-8 [10396297.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):432-9 [15548351.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8534-40 [15574759.001]
  • [Cites] Oncogene. 2005 Mar 3;24(10):1794-801 [15688027.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Sep;44(1):37-51 [15929091.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):556-62 [16036106.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8235-42 [16322280.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4149-58 [16618736.001]
  • [Cites] Oncogene. 2006 Jun 1;25(23):3247-57 [16491129.001]
  • [Cites] Trends Genet. 2006 Aug;22(8):447-55 [16787682.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1943-9 [17332321.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Apr;48(4):330-9 [19145645.001]
  • (PMID = 20232484.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109552-01A1; United States / NCI NIH HHS / CA / P01 CA109552; United States / NCI NIH HHS / CA / P01 CA109552-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS189142; NLM/ PMC2855495
  •  go-up   go-down


62. Abdullah M, Schultz H, Kähler D, Branscheid D, Dalhoff K, Zabel P, Vollmer E, Goldmann T: Expression of the acute phase protein haptoglobin in human lung cancer and tumor-free lung tissues. Pathol Res Pract; 2009;205(9):639-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-seven specimens were subjected to mRNA-in situ hybridization.
  • 40.4% of the adenocarcinomas showed distinct granular and perinuclear staining of the tumor cells.
  • In situ hybridization verified the results of immunohistochemistry.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Blotting, Western. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Humans. Immunohistochemistry. In Situ Hybridization. Reverse Transcriptase Polymerase Chain Reaction. Small Cell Lung Carcinoma / metabolism. Small Cell Lung Carcinoma / pathology. Tissue Array Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19501987.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Haptoglobins
  •  go-up   go-down


63. Pavlakis K, Messini I, Athanassiadou S, Kyrodimou E, Pandazopoulou A, Vrekoussis T, Stathopoulos EN: Endocervical glandular lesions: a diagnostic approach combining a semi-quantitative scoring method to the expression of CEA, MIB-1 and p16. Gynecol Oncol; 2006 Dec;103(3):971-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The hematoxylin and eosin-stained sections of 95 cervical biopsies were examined by 4 different observers and were grouped into three categories, benign, dysplasia and adenocarcinoma in situ, depending on the degree of nuclear stratification, nuclear atypia and the number of mitosis and apoptotic figures.
  • This scoring system discriminates effectively (Kruskal-Wallis, p<0.001) between the three categories (benign, endocervical glandular dysplasia and adenocarcinoma in situ).
  • Nevertheless, the proportion of cases that were classified similarly to the prestudy diagnosis was higher when the combined score was used.
  • [MeSH-major] Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / metabolism


64. Matsumura M, Ota T, Takeshima N, Takizawa K: Shimodaira-Taniguchi conization method: its utility and reliability. Int J Gynecol Cancer; 2010 Aug;20(6):1025-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted a retrospective study to evaluate Shimodaira-Taniguchi conization as a conservative therapy for cervical intraepithelial neoplasia (CIN) and microinvasive cancer of the cervix.
  • METHODS: Subjects were 455 patients who underwent Shimodaira-Taniguchi conization for CIN, carcinoma in situ, adenocarcinoma in situ, or stage IA microinvasive cervical carcinoma at our hospital from January 2005 to December 2008.
  • None were lost to follow-up, and there was no disease-related death.
  • Disease recurred in 6 (1.3%) patients: 4 with a positive excision margin and 2 with a negative margin.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / surgery. Conization / methods. Neoplasm Recurrence, Local / epidemiology. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683412.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Sakuma Y, Matsukuma S, Yoshihara M, Nakamura Y, Noda K, Nakayama H, Kameda Y, Tsuchiya E, Miyagi Y: Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol; 2007 Jul;128(1):100-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.
  • Although adenocarcinomas of the lung are associated with epidermal growth factor receptor (EGFR) gene mutations and sensitivity to EGFR tyrosine kinase inhibitors, it remains unclear whether bronchioloalveolar carcinoma (BAC) components and/or subtypes affect these associations.
  • We examined 141 non-small cell lung cancers (NSCLCs), including 118 adenocarcinomas, for mutations in exons 19 and 21 of the EGFR gene together with mutations in codon 12 of the K-ras gene using loop-hybrid mobility shift assays, a highly sensitive polymerase chain reaction-based method.
  • Adenocarcinomas were subdivided into subtypes with a nonmucinous or mucinous BAC component and those without BAC components.
  • In NSCLCs, EGFR mutations were detected in 75 cases (53.2%) and were significantly associated with adenocarcinoma, female sex, and never smoking.
  • Among adenocarcinomas, nonmucinous and mucinous BAC components were significantly associated with EGFR and K-ras gene mutations, respectively.
  • Because EGFR mutations were detected even in most pure nonmucinous BACs, ie, lung adenocarcinoma in situ, EGFR mutation is considered a critical event in the pathogenesis of nonmucinous BAC tumors.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Genes, ras. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580276.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


66. Modem RR, Otis CN, Florence RR, Pantanowitz L: Intestinal type adenocarcinoma in situ of the cervix. Diagn Cytopathol; 2007 Sep;35(9):584-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal type adenocarcinoma in situ of the cervix.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Intestinal Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Cytological Techniques. Diagnosis, Differential. Female. Humans. Vaginal Smears


67. Martinek J, Benes M, Brandtl P, Hucl T, Vasicek M, Voska L, Lanska V, Nosek V, Spicak J: Low incidence of adenocarcinoma and high-grade intraepithelial neoplasia in patients with Barrett's esophagus: a prospective cohort study. Endoscopy; 2008 Sep;40(9):711-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low incidence of adenocarcinoma and high-grade intraepithelial neoplasia in patients with Barrett's esophagus: a prospective cohort study.
  • The risk of developing high grade intraepithelial neoplasia (HGIN) or adenocarcinoma is currently a matter of debate.
  • The main aim of our study was to investigate the incidence of HGD and adenocarcinoma in a cohort of patients with Barrett's esophagus.
  • Simultaneous HGIN and adenocarcinoma were detected in two patients with long-segment Barrett's esophagus (1.5%; 2 and 6 years after the index endoscopy).
  • Low grade intraepithelial neoplasia (LGIN) was detected in 25 patients (18.5%); in 11 of these patients (44%), LGIN was not confirmed in later biopsies.
  • Our study shows an incidence of HGIN/adenocarcinoma of 1/350 patient-years.
  • CONCLUSION: The incidence of HGIN/adenocarcinoma is low in patients with adequately treated Barrett's esophagus.
  • The annual risk of developing HGIN/adenocarcinoma is 0.21% (1.6% in long-segment Barrett's esophagus).
  • [MeSH-major] Adenocarcinoma / epidemiology. Barrett Esophagus / epidemiology. Carcinoma in Situ / epidemiology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698534.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


68. Crippa S, Salvia R, Warshaw AL, Domínguez I, Bassi C, Falconi M, Thayer SP, Zamboni G, Lauwers GY, Mino-Kenudson M, Capelli P, Pederzoli P, Castillo CF: Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg; 2008 Apr;247(4):571-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One hundred eighteen patients (72%) had adenoma, 17 (10.5%) borderline tumors, 9 (5.5%) in situ carcinoma, and 19 (12%) invasive carcinoma.
  • The 5-year disease-specific survival for noninvasive MCNs was 100%, and for those with invasive cancer, 57%.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenoma / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1320-7 [10555000.001]
  • [Cites] Ann Surg. 2000 Feb;231(2):205-12 [10674612.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):139-52 [11812936.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):164-8 [11822953.001]
  • [Cites] Pancreatology. 2002;2(5):484-90 [12378117.001]
  • [Cites] Oncol Rep. 2003 May-Jun;10(3):515-25 [12684617.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):198-205 [12892797.001]
  • [Cites] Am J Surg Pathol. 2003 Sep;27(9):1221-8 [12960806.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1040-4 [15020606.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] J Gastrointest Surg. 2004 May-Jun;8(4):493-501 [15120376.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):168-78 [15185076.001]
  • [Cites] Am J Clin Pathol. 1978 Jun;69(6):573-80 [665578.001]
  • [Cites] Surg Gynecol Obstet. 1987 Dec;165(6):475-8 [2446398.001]
  • [Cites] Arch Surg. 1988 May;123(5):550-3 [3358679.001]
  • [Cites] Ann Surg. 1990 Oct;212(4):432-43; discussion 444-5 [2171441.001]
  • [Cites] Pancreas. 1991 Jan;6(1):15-22 [1994377.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1078-91 [7943529.001]
  • [Cites] Virchows Arch. 1994;424(1):53-7 [7981904.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):896-903 [9637553.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):1-16 [9888699.001]
  • [Cites] Am Surg. 1999 Feb;65(2):105-11 [9926740.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Ann Surg. 1999 May;229(5):693-8; discussion 698-700 [10235528.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Nov;2(11):1026-31 [15551256.001]
  • [Cites] Int J Gynecol Pathol. 2005 Jan;24(1):4-25 [15626914.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S19-32 [15761464.001]
  • [Cites] J Am Coll Surg. 2005 May;200(5):727-33 [15848365.001]
  • [Cites] Surgery. 2005 Jun;137(6):597-605 [15962401.001]
  • [Cites] Pancreas. 2005 Jul;31(1):79-83 [15968252.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] Hum Pathol. 2005 Aug;36(8):927-31 [16112012.001]
  • [Cites] Arch Surg. 2006 Jan;141(1):51-6; discussion 56 [16415411.001]
  • [Cites] Pathol Int. 2006 Feb;56(2):71-7 [16445818.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):904-13 [16508639.001]
  • [Cites] Arch Surg. 2006 Apr;141(4):361-5; discussion 366 [16618893.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Dig Surg. 2006;23(3):186-91 [16837797.001]
  • [Cites] World J Surg. 2006 Dec;30(12):2236-45 [17103100.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):69-76 [17592293.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):77-82 [17592294.001]
  • [Cites] Br J Surg. 2007 Oct;94(10):1254-9 [17583892.001]
  • [Cites] Br J Surg. 2008 Jan;95(1):85-91 [18041022.001]
  • [CommentIn] Ann Surg. 2008 Apr;247(4):580-2 [18362620.001]
  • (PMID = 18362619.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK071329
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS517373; NLM/ PMC3806104
  •  go-up   go-down


69. Sheahan P, Toner M, Timon CV: Clinicopathological features of head and neck adenosquamous carcinoma. ORL J Otorhinolaryngol Relat Spec; 2005;67(1):10-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenosquamous carcinoma is a rare tumour which is characterized pathologically by the simultaneous presence of distinct areas of squamous cell carcinoma and adenocarcinoma.
  • In 1 patient, the tumour arose from an area of carcinoma in situ of surface epithelium.
  • One patient died of postoperative complications, 1 suffered from local recurrence and developed distant metastases and 2 were alive with no evidence of disease over 30 months later.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15637416.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


70. Anderson WF, Devesa SS: In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute. Cancer; 2005 Oct 15;104(8):1733-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute.
  • BACKGROUND: In situ breast carcinoma is not so well characterized for men as for women.
  • METHODS: Therefore, the authors of the current study compared male and female in situ and invasive breast carcinomas in the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute to document these patterns.
  • RESULTS: In situ breast carcinomas composed 9.4% of all male (n = 280 of 2984) and 11.9% of all female breast carcinomas (n = 53,928 of 454,405) during the years 1973-2001.
  • In situ rates rose 123% for men and 555% for women over this time period; whereas distant disease rates fell for both genders.
  • Median ages at diagnosis were 62 years for in situ and 68 years for invasive breast carcinoma among men, compared with 58 years for in situ and 62 years for invasive breast carcinoma among women.
  • Papillary in situ and invasive architectural types were more common among men than women.
  • CONCLUSION: In situ male breast carcinoma is a rare disease, occurring at older ages and with different architectural types than its more common female counterpart.
  • Rising in situ male breast carcinoma incidence rates over the past three decades suggest earlier detection over time, irrespective of mammography, because men do not participate in routine screening mammography.
  • [MeSH-minor] Adenocarcinoma, Mucinous / epidemiology. Aged. Aged, 80 and over. Breast Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Invasiveness. Neoplasms, Ductal, Lobular, and Medullary / epidemiology. Risk Factors. Survival Rate. United States / epidemiology


71. Ouaïssi M, Sielezneff I, Alves A, Pirro N, Heyries L, Robitail S, Consentino B, Payan MJ, Valleur P, Panis Y, Sastre B: [Long term outcome following 26 surgical ampullectomies]. Ann Chir; 2006 May;131(5):322-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Final pathological examination revealed 15 adenomas, 4 in situ adenocarcinomas, 2 endocrine tumors, and 5 other benign lesions.
  • Four patients died during follow-up (including 3 from initial disease).
  • [MeSH-minor] Adenocarcinoma / surgery. Adenoma / surgery. Adenomatous Polyposis Coli / surgery. Adult. Aged. Carcinoma in Situ / surgery. Cause of Death. Common Bile Duct Diseases / surgery. Female. Follow-Up Studies. Granuloma, Plasma Cell / surgery. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Retrospective Studies. Somatostatinoma / surgery. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615931.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


72. Ohe C, Sakaida N, Tadokoro C, Fukui H, Asako M, Tomoda K, Uemura Y: Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: report of two cases. Pathol Int; 2010 Feb;60(2):107-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: report of two cases.
  • Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma (LGNPPA) is extremely rare; only four cases have been reported.
  • In situ hybridization for EBV was negative.
  • Nasopharyngeal tumors with similar morphological appearance should be examined for TTF-1 immunoreactivity, and patients should be clinically followed to determine the course of this unusual disease and the significance of TTF-1 expression.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Nasopharyngeal Neoplasms / pathology. Nuclear Proteins / biosynthesis. Transcription Factors / biosynthesis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398195.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


73. Li X, Zhang Q, Cai L, Wang Y, Wang Q, Huang X, Fu S, Bai J, Liu J, Zhang G, Qi J: Inhibitor of growth 4 induces apoptosis in human lung adenocarcinoma cell line A549 via Bcl-2 family proteins and mitochondria apoptosis pathway. J Cancer Res Clin Oncol; 2009 Jun;135(6):829-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitor of growth 4 induces apoptosis in human lung adenocarcinoma cell line A549 via Bcl-2 family proteins and mitochondria apoptosis pathway.
  • In present study, the effects of ING4 on apoptosis and its mechanisms were investigated through the transduction of ING4 cDNA into lung adenocarcinoma cell line A549.
  • [MeSH-major] Adenocarcinoma / physiopathology. Apoptosis / physiology. Cell Cycle Proteins / physiology. Homeodomain Proteins / physiology. Lung Neoplasms / physiopathology. Mitochondria / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Animals. Blotting, Western. Caspase 3 / metabolism. Cell Line, Tumor. Cytochromes c / metabolism. Flow Cytometry. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Lung / metabolism. Lung / pathology. Lung / ultrastructure. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Microscopy, Electron. Neoplasm Transplantation. Signal Transduction / physiology. Transfection. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Biochem Sci. 2001 Jan;26(1):61-6 [11165519.001]
  • [Cites] Cell. 2002 Nov 1;111(3):331-42 [12419244.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 27;262(2):381-7 [10462484.001]
  • [Cites] Mol Cell. 2001 Sep;8(3):705-11 [11583631.001]
  • [Cites] Lung Cancer. 2006 Jan;51(1):61-9 [16297499.001]
  • [Cites] J Cell Biol. 1999 Mar 8;144(5):891-901 [10085289.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2007 Jun;28(6):396-400 [17939406.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27432-40 [11369777.001]
  • [Cites] Anat Rec (Hoboken). 2008 May;291(5):593-600 [18399550.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2373-8 [12750254.001]
  • [Cites] FEBS Lett. 2004 Jul 16;570(1-3):7-12 [15251430.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16251-6 [15528276.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):13-8 [11316541.001]
  • [Cites] Gene. 2005 Aug 15;356:109-17 [15935570.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):19-30 [12086884.001]
  • [Cites] Nature. 2004 Mar 18;428(6980):328-32 [15029197.001]
  • (PMID = 19034511.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Homeodomain Proteins; 0 / ING4 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Proteins; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


74. Tokunaga H, Takebayashi Y, Utsunomiya H, Akahira J, Higashimoto M, Mashiko M, Ito K, Niikura H, Takenoshita S, Yaegashi N: Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer. Acta Obstet Gynecol Scand; 2008;87(10):1060-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Localized circadian gene expression was determined in cancer cells by in situ hybridization analysis.
  • Bmal1 expression was also significantly reduced in mucinous adenocarcinomas as compared to other histologies.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Cell Cycle Proteins / biosynthesis. Circadian Rhythm / genetics. Gene Expression Regulation, Neoplastic / physiology. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Female. Humans. In Situ Hybridization. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18720043.001).
  • [ISSN] 1600-0412
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm
  •  go-up   go-down


75. Boelens MC, van den Berg A, Vogelzang I, Wesseling J, Postma DS, Timens W, Groen HJ: Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus. J Clin Pathol; 2007 Jun;60(6):608-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemistry (IHC) and RNA in situ hybridisation (ISH) were used to confirm the most prominently expressed adhesion molecules and to investigate their distribution at protein and mRNA levels.
  • RESULTS: 43 differentially expressed cancer-related genes were identified in adenocarcinoma, squamous cell carcinoma (SCC) and normal bronchus.
  • ITGA3 and ITGB4, showing predominantly cell-matrix staining, were up regulated in adenocarcinoma and SCC, respectively.
  • A possible association of strong presence and normal-distributed desmosomal molecules in SCC with the less frequent and late pattern of metastasis in SCC as compared with adenocarcinoma is suggested.
  • [MeSH-minor] Adenocarcinoma / metabolism. Aged. Bronchi / metabolism. Carcinoma, Small Cell / metabolism. Desmosomes / metabolism. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. In Situ Hybridization. Integrins / metabolism. Male. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Up-Regulation

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):823-30 [11533662.001]
  • [Cites] Ann N Y Acad Sci. 2000;915:144-50 [11193570.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3005-8 [12036904.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3244-50 [12036940.001]
  • [Cites] Mol Membr Biol. 2002 Apr-Jun;19(2):81-94 [12126234.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Curr Opin Cell Biol. 2002 Oct;14(5):537-45 [12231347.001]
  • [Cites] Oncogene. 2003 Apr 10;22(14):2192-205 [12687021.001]
  • [Cites] Cancer Biol Ther. 2003 May-Jun;2(3):291-8 [12878869.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:207-35 [14570569.001]
  • [Cites] Cancer Biol Ther. 2003 Sep-Oct;2(5):566-71 [14614329.001]
  • [Cites] Oncol Rep. 2004 May;11(5):1041-4 [15069544.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Apr;5(4):271-81 [15071552.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 May;127(5):1332-41; discussion 1342 [15115990.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10143-8 [15210990.001]
  • [Cites] Cell. 1986 Sep 26;46(7):1063-73 [3530498.001]
  • [Cites] Am J Respir Cell Mol Biol. 1992 Feb;6(2):197-206 [1540382.001]
  • [Cites] Int J Cancer. 1995 Aug 22;64(4):248-52 [7657388.001]
  • [Cites] J Exp Ther Oncol. 2004 Jul;4(2):155-60 [15500010.001]
  • [Cites] Cancer Metastasis Rev. 1995 Sep;14(3):229-39 [8548871.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7701-5 [8755539.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Hum Pathol. 1997 Sep;28(9):1018-25 [9308725.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1060-7 [9508191.001]
  • [Cites] J Pathol. 1998 Apr;184(4):369-81 [9664902.001]
  • [Cites] Differentiation. 1998 Sep;63(5):295-304 [9810708.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1208-15 [9824097.001]
  • [Cites] J Surg Res. 2004 Nov;122(1):61-9 [15522316.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • (PMID = 16489176.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Integrins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC1955047
  •  go-up   go-down


76. Canchola AJ, Horn-Ross PL, Purdie DM: Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol; 2006 Mar 15;163(6):521-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Second malignancies in women diagnosed with thyroid cancer are of concern given the young average age at diagnosis and excellent survival.
  • Follow-up was calculated from 2 months until the diagnosis of a second primary cancer, death, loss to follow-up, or December 31, 1999, whichever occurred first.
  • An excess of in situ breast cancer (SIR = 1.6, 95% CI: 1.0, 2.4), kidney cancer (SIR = 3.9, 95% CI: 2.2, 6.3), and melanoma (SIR = 2.1, 95% CI: 1.3, 3.2) limited to the first 5 years after diagnosis was observed.
  • Women with papillary thyroid cancer are at increased risk of in situ, but not invasive, breast cancer, kidney cancer, and melanoma.
  • [MeSH-major] Adenocarcinoma, Papillary / epidemiology. Breast Neoplasms / epidemiology. Kidney Neoplasms / epidemiology. Melanoma / epidemiology. Neoplasms, Second Primary / epidemiology. Thyroid Neoplasms / epidemiology


77. Esposito I, Kleeff J, Abiatari I, Shi X, Giese N, Bergmann F, Roth W, Friess H, Schirmacher P: Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer. J Clin Pathol; 2007 Aug;60(8):885-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: cIAP1 expression was constantly high in non-neoplastic pancreatic tissues, in pancreatic intraepithelial neoplasia (PanIN) lesions, as well as in a subset of primary and metastatic pancreatic ductal adenocarcinomas (PDAC), and a preferential cytoplasmatic localisation was observed in the tumour tissues. cIAP1 expression was rare in a cohort of cystic tumours. cIAP2 mRNA levels were significantly higher (2.4 fold) in PDAC than in normal tissues. cIAP2 protein was overexpressed in PDAC, and was detectable in low- and high-grade PanIN lesions.
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Adult. Aged. Carcinoma in Situ / chemistry. Carcinoma in Situ / pathology. Cell Line, Tumor. Chronic Disease. Cysts / chemistry. Cytoplasm / chemistry. Cytoplasm / pathology. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Immunohistochemistry / methods. Male. Middle Aged. Pancreas / chemistry. Pancreas / pathology. Pancreatitis / genetics. Pancreatitis / pathology. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Survival Analysis


78. Ohike N, Kim GE, Tajiri T, Krasinskas A, Basturk O, Coban I, Bandyopadhyay S, Morohoshi T, Goodman M, Kooby DA, Sarmiento JM, Adsay NV: Intra-ampullary papillary-tubular neoplasm (IAPN): characterization of tumoral intraepithelial neoplasia occurring within the ampulla: a clinicopathologic analysis of 82 cases. Am J Surg Pathol; 2010 Dec;34(12):1731-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-ampullary papillary-tubular neoplasm (IAPN): characterization of tumoral intraepithelial neoplasia occurring within the ampulla: a clinicopathologic analysis of 82 cases.
  • BACKGROUND: There has been no uniform terminology for systematic analysis of mass-forming preinvasive neoplasms (which we term tumoral intraepithelial neoplasia) that occur specifically within the ampulla.
  • Here, we provide a detailed analysis of these neoplasms, which we propose to refer to as intra-ampullary papillary-tubular neoplasm (IAPN).
  • Eighty-two neoplasms characterized by substantial preinvasive exophytic component that grew almost exclusively (>75%) within the ampulla (in the ampullary channel or intra-ampullary portions of the very distal segments of the common bile duct or pancreatic duct) were analyzed. RESULTS:.
  • Cell lineage in the invasive component was the same as that of the preinvasive component in 84%.
  • All discrepant cases were pancreatobiliary-type invasions, which occurred in INT-type preinvasive lesions. (5) OUTCOME: The overall survival of invasive cases were significantly worse than that of noninvasive ones (57% vs. 93%; P=0.01); and 3 years, 69% versus 100% (P=0.08); and 5 years, 45% versus 100% (P=0.07), respectively.
  • CONCLUSIONS: Tumoral intraepithelial neoplasia occurring within the ampulla are highly analogous to pancreatic or biliary intraductal papillary and tubular neoplasms as evidenced by their papillary and/or tubular growth, variable cell lineage, and spectrum of dysplastic change (adenoma-carcinoma sequence), and thus we propose to refer to these as IAPN.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Anat Pathol. 2004 Mar;11(2):101-5 [15090846.001]
  • [Cites] Arch Pathol Lab Med. 2009 Mar;133(3):423-38 [19260748.001]
  • [Cites] J Clin Pathol. 2004 May;57(5):456-62 [15113850.001]
  • [Cites] Med Sci Monit. 2004 May;10(5):BR139-43 [15114262.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):839-48 [15223952.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Pancreas. 2004 Aug;29(2):116-22 [15257103.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):506-15 [3791159.001]
  • [Cites] Dig Dis Sci. 1989 Feb;34(2):167-70 [2536604.001]
  • [Cites] Mod Pathol. 1994 Apr;7(3):376-84 [8058711.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):980-94 [8712298.001]
  • [Cites] Pathol Int. 1998 Apr;48(4):319-22 [9648163.001]
  • [Cites] Pancreas. 2005 Mar;30(2):115-21 [15714133.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):794-9 [16088402.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):350-8 [16360234.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):249-50 [16360969.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1243-54 [16741522.001]
  • [Cites] Hepatology. 2006 Nov;44(5):1333-43 [17058219.001]
  • [Cites] World J Gastroenterol. 2007 Feb 21;13(7):1108-11 [17373748.001]
  • [Cites] J Hepatol. 2007 May;46(5):978-9 [17391800.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):243-54 [17520199.001]
  • [Cites] Pathology. 2007 Aug;39(4):413-8 [17676483.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(5):526-8 [17909726.001]
  • [Cites] Abdom Imaging. 2007 Sep-Oct;32(5):644-51 [17437076.001]
  • [Cites] Endoscopy. 2000 May;32(5):389-93 [10817178.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):870-6 [10843291.001]
  • [Cites] Arch Pathol Lab Med. 2000 Aug;124(8):1196-200 [10923083.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):508-15 [10931449.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):962-72 [11007036.001]
  • [Cites] Mod Pathol. 2000 Dec;13(12):1300-7 [11144926.001]
  • [Cites] Am J Clin Pathol. 2001 May;115(5):695-702 [11345833.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] J Gastrointest Surg. 2009 Aug;13(8):1510-6 [19440799.001]
  • [Cites] Am J Surg Pathol. 2009 Aug;33(8):1164-72 [19440145.001]
  • [Cites] J Surg Oncol. 2009 Dec 1;100(7):598-605 [19697352.001]
  • [Cites] Ann Surg. 2010 Mar;251(3):470-6 [20142731.001]
  • [Cites] Am J Surg Pathol. 2010 Mar;34(3):364-70 [20139757.001]
  • [Cites] Mod Pathol. 2001 Dec;14(12):1304-9 [11743055.001]
  • [Cites] Korean J Radiol. 2002 Jan-Mar;3(1):57-63 [11919480.001]
  • [Cites] Eur J Cancer. 2002 Apr;38(6):758-63 [11937308.001]
  • [Cites] Chirurg. 2002 Mar;73(3):235-40 [11963497.001]
  • [Cites] Arch Surg. 2002 May;137(5):557-62; discussion 562-3 [11982469.001]
  • [Cites] J Pathol. 2002 Jun;197(2):201-10 [12015744.001]
  • [Cites] Am J Clin Pathol. 2002 Jun;117(6):944-51 [12047147.001]
  • [Cites] Dig Surg. 2002;19(4):324-7 [12207078.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):391-400 [12352188.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(3):328-41 [12353144.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1087-95 [12379756.001]
  • [Cites] Mod Pathol. 2002 Dec;15(12):1309-17 [12481012.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):303-10 [12604886.001]
  • [Cites] Pathol Int. 2002 Nov;52(11):713-23 [12685548.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):571-8 [12717243.001]
  • [Cites] Mod Pathol. 2003 May;16(5):403-10 [12748245.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):913-9 [13679455.001]
  • [Cites] Hum Pathol. 2003 Sep;34(9):902-10 [14562286.001]
  • [Cites] Proteomics. 2008 Aug;8(16):3329-41 [18651706.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):327-38 [15104295.001]
  • (PMID = 21084962.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA101936; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / P50 CA062924-18; United States / NCI NIH HHS / CA / CA101936
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS315774; NLM/ PMC3168573
  •  go-up   go-down


79. Yang ZM, Han XP, Wu SF, Yin YF, Wang K, Gao J, Liang ZY, Zeng X: [Analysis of chromosomal abnormalities in pancreatic cancer by spectral karyotyping]. Zhonghua Bing Li Xue Za Zhi; 2010 Nov;39(11):767-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: to investigate the chromosomal characteristics of pancreatic ductal adenocarcinomas by spectral karyotyping.
  • Chromosomal alterations were further evaluated in 10 cases of pancreatic cancer and 10 cases of chronic pancreatitis by two color fluorescence in situ hybridization (FISH) by using EGFR/CEP7 probe and paraffin embedded tissue samples.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Genes, erbB-1 / genetics. Karyotyping / methods. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Aged. Cell Line, Tumor. Chromosome Deletion. Chromosome Duplication. Female. Gene Dosage. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged


80. Sugamura K, Gibbs JF, Belicha-Villanueva A, Andrews C, Repasky EA, Hylander BL: Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts. Oncology; 2008;74(3-4):188-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using this model, our laboratory has previously demonstrated that the growth of several human adenocarcinomas can be inhibited by Apo2L/TRAIL.
  • METHODS: To gain further insight into the antitumor potential of Apo2L/TRAIL in combination with chemotherapy, we compared the responses of 2 human colon adenocarcinomas, both of which were sensitive to CPT-11 while one was sensitive and the other comparatively resistant to Apo2L/TRAIL.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1583-7 [11912124.001]
  • [Cites] Nat Med. 2002 Mar;8(3):274-81 [11875499.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5800-6 [12384541.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):337-48 [12787570.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4713-23 [12907654.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4227-39 [14519650.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15095-100 [14645705.001]
  • [Cites] Curr Opin Pharmacol. 2004 Aug;4(4):333-9 [15251125.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4900-5 [15256461.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9345-9 [1924398.001]
  • [Cites] Immunity. 1995 Dec;3(6):673-82 [8777713.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):12687-90 [8663110.001]
  • [Cites] Science. 1997 Apr 4;276(5309):111-3 [9082980.001]
  • [Cites] Science. 1997 Aug 8;277(5327):818-21 [9242611.001]
  • [Cites] EMBO J. 1997 Sep 1;16(17):5386-97 [9311998.001]
  • [Cites] Immunity. 1997 Dec;7(6):831-6 [9430228.001]
  • [Cites] Oncogene. 1999 Jan 7;18(1):211-8 [9926936.001]
  • [Cites] Nat Med. 1999 Feb;5(2):157-63 [9930862.001]
  • [Cites] Genes Dev. 1999 Feb 1;13(3):239-52 [9990849.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):2026-36 [16373718.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):335-46 [10690508.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6153-8 [10626806.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4652-61 [16899615.001]
  • [Cites] J Pathol. 2000 Mar;190(4):450-6 [10699994.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):847-53 [10706092.001]
  • [Cites] J Immunol. 2000 Apr 15;164(8):3961-70 [10754286.001]
  • [Cites] Cell Immunol. 2000 May 1;201(2):77-82 [10831316.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1645-51 [11245478.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1424-31 [11355958.001]
  • [Cites] Oncogene. 2001 Jun 28;20(29):3757-65 [11439339.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1650-7 [11587225.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7556-62 [11606394.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3874-83 [11751478.001]
  • [Cites] Nat Med. 2002 Mar;8(3):216-8 [11875486.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]
  • (PMID = 18714167.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / R01 CA108888; United States / NCI NIH HHS / CA / CA108888-01A1; United States / NCI NIH HHS / CA / P30CA016056
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / Topoisomerase I Inhibitors; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2826876
  •  go-up   go-down


81. Agostinelli E, Tempera G, Dalla Vedova L, Condello M, Arancia G: MDL 72527 and spermine oxidation products induce a lysosomotropic effect and mitochondrial alterations in tumour cells. Biochem Soc Trans; 2007 Apr;35(Pt 2):343-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytotoxic products of polyamines generated in situ by an enzyme-catalysed reaction may be useful as a new avenue in combating cancer.
  • This study demonstrated that MDR (multidrug-resistant) cancer cells (colon adenocarcinoma and melanoma) are significantly more sensitive than the corresponding WT (wild-type) ones to H(2)O(2) and aldehydes, the products of BSAO (bovine serum amine oxidase)-catalysed oxidation of spermine.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Putrescine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Biochem Soc Trans. 2013 Dec;41(6):1773
  • (PMID = 17371275.001).
  • [ISSN] 0300-5127
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 2FZ7Y3VOQX / Spermine; 93565-01-6 / MDL 72527; V10TVZ52E4 / Putrescine
  •  go-up   go-down


82. Okoń K, Demczuk S, Klimkowska A, Wójcik P, Osuch C, Papla B, Stachura J: Correlation of microsatellite status, proliferation, apoptotic and selected immunohistochemical markers in colorectal carcinoma studied with tissue microarray. Pol J Pathol; 2006;57(2):105-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma. Apoptosis. Biomarkers, Tumor / analysis. Colorectal Neoplasms. Microsatellite Repeats. Tissue Array Analysis / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Proliferation. Discriminant Analysis. Female. Humans. Immunoenzyme Techniques. In Situ Nick-End Labeling. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17019973.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


83. Weinreb I, Perez-Ordoñez B, Guha A, Kiehl TR: Mucinous, gland predominant synovial sarcoma of a large peripheral nerve: a rare case closely mimicking metastatic mucinous carcinoma. J Clin Pathol; 2008 May;61(5):672-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis was confirmed by molecular detection of the t(X;18) by reverse transcription-PCR and confirmed by dual colour break apart fluorescence in situ hybridisation, in a second laboratory.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Peripheral Nervous System Neoplasms / diagnosis. Sarcoma, Synovial / diagnosis

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18441160.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


84. Yoo KJ, Lee HJ, Lee H, Lee KY, Lee SH, Chung HM, Baek KH: Expression and functional analyses of mHAUSP regulating apoptosis of cervical adenocarcinoma cells. Int J Oncol; 2005 Jul;27(1):97-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and functional analyses of mHAUSP regulating apoptosis of cervical adenocarcinoma cells.
  • In situ hybridization study showed the global expression of mHAUSP in various organs of embryos, including mesencephalon, spinal cord, lung and genital eminence.
  • [MeSH-minor] Amino Acid Sequence. Animals. Blotting, Northern. Catalytic Domain. Conserved Sequence. Female. Genitalia / embryology. HeLa Cells. Humans. In Situ Hybridization. Lung / embryology. Mesencephalon / metabolism. Mice. Models, Genetic. Molecular Sequence Data. Mutagenesis, Site-Directed. Plasmids / metabolism. Point Mutation. Protein Structure, Tertiary. Spinal Cord / embryology. Time Factors. Tissue Distribution. Tumor Suppressor Protein p53 / metabolism. Ubiquitin / metabolism. Ubiquitin Thiolesterase


85. Skórzewska K, Radowicki S, Matuszkiewicz-Rowinska J, Szlendak-Sauer K: Morphological changes in endometrium of hemodialyzed women of reproductive age. Gynecol Endocrinol; 2007 Sep;23(9):523-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrial biopsy revealed one case of adenocarcinoma in situ.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17943547.001).
  • [ISSN] 0951-3590
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 3XMK78S47O / Testosterone; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


86. Stanley M: Human papillomavirus vaccines versus cervical cancer screening. Clin Oncol (R Coll Radiol); 2008 Aug;20(6):388-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prophylactic vaccination with human papillomavirus (HPV) virus-like particle (VLP) vaccines against HPV 16 and HPV 18, which are the cause of 70% or more of cervical cancers in women, has transformed our prospects for reducing the incidence of this disease on a global scale.
  • HPV VLP vaccines are immunogenic, well tolerated and show remarkable efficacy, achieving >98% protection in randomised clinical trials against the obligate precursor lesions cervical intraepithelial neoplasia grade 2/3 (CIN2/3) and adenocarcinoma in situ.
  • Screening will have to continue, as only two of the 15 oncogenic HPV types are in the vaccines and for two to three decades at least unvaccinated sexually active women will remain at risk for the disease.
  • [MeSH-minor] Cervical Intraepithelial Neoplasia / prevention & control. Cervical Intraepithelial Neoplasia / virology. Female. Great Britain / epidemiology. Human papillomavirus 16 / drug effects. Human papillomavirus 16 / immunology. Human papillomavirus 18 / drug effects. Human papillomavirus 18 / immunology. Humans. Risk Factors


87. Grützmann R, Niedergethmann M, Pilarsky C, Klöppel G, Saeger HD: Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. Oncologist; 2010;15(12):1294-309
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment.
  • For a long time they were misdiagnosed as mucinous cystadenocarcinoma, ductal adenocarcinoma in situ, or chronic pancreatitis.
  • When resected in a preinvasive state patient prognosis is excellent, and even when they are already invasive, patient prognosis is more favorable than with ductal adenocarcinomas.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / therapy. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / therapy. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / therapy. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 2004 Oct;29(3):212-7 [15367887.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1329-35 [2548703.001]
  • [Cites] Cancer. 1991 Jul 1;68(1):159-68 [2049738.001]
  • [Cites] Gut. 2008 Mar;57(3):339-43 [17660227.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):645-50 [18097728.001]
  • [Cites] Dig Surg. 2008;25(1):46-51 [18292661.001]
  • [Cites] Oncol Rep. 2008 May;19(5):1185-90 [18425375.001]
  • [Cites] J Gastrointest Surg. 2008 Jun;12(6):1127-32 [18299945.001]
  • [Cites] Abdom Imaging. 2008 Jul-Aug;33(4):474-81 [17680299.001]
  • [Cites] Pancreatology. 2008;8(3):277-84 [18497541.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:10 [18577196.001]
  • [Cites] Arch Surg. 2008 Jul;143(7):639-46; discussion 646 [18645105.001]
  • [Cites] AJR Am J Roentgenol. 2008 Sep;191(3):802-7 [18716113.001]
  • [Cites] World J Surg. 2008 Oct;32(10):2253-60 [18668283.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2737-41 [18843017.001]
  • [Cites] Gut. 2008 Nov;57(11):1561-5 [18477671.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3187-92 [18766406.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Am J Gastroenterol. 2000 Apr;95(4):961-5 [10763945.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):26-42 [11145249.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1047-53 [11474289.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):62-77 [11815961.001]
  • [Cites] J Pathol. 2002 Jun;197(2):201-10 [12015744.001]
  • [Cites] Gut. 2002 Sep;51(3):446-9 [12171972.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):543-7 [12297771.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Arch Surg. 2002 Nov;137(11):1274-8 [12413317.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):193-8 [12584167.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1505-13 [1516002.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):980-94 [8712298.001]
  • [Cites] Gut. 1996 Sep;39(3):457-64 [8949654.001]
  • [Cites] World J Surg. 1998 Aug;22(8):874-8 [9673562.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Adv Anat Pathol. 1999 Mar;6(2):65-77 [10331069.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1835-40 [10362809.001]
  • [Cites] J Gastrointest Surg. 2008 Feb;12(2):234-42 [18040749.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3193-8 [18784959.001]
  • [Cites] Mod Pathol. 2008 Dec;21(12):1499-507 [18820670.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2871-7 [18775021.001]
  • [Cites] Gastrointest Endosc. 2009 Feb;69(2 Suppl):S203-9 [19179158.001]
  • [Cites] Pancreas. 2009 Mar;38(2):131-6 [18981954.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • [Cites] Arch Surg. 1999 Oct;134(10):1131-6 [10522860.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):144-52 [15654794.001]
  • [Cites] Pathologe. 2005 Feb;26(1):22-30 [15624092.001]
  • [Cites] Am J Surg. 2005 May;189(5):632-6; discussion 637 [15862510.001]
  • [Cites] J Gastroenterol. 2005 May;40(5):518-25 [15942718.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4681-8 [16000561.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1034-42 [15832194.001]
  • [Cites] Pancreas. 2005 Nov;31(4):344-9 [16258368.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):800-5 [16021508.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):794-9 [16088402.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):774-8, discussion 778-80 [16327487.001]
  • [Cites] World J Surg. 2005 Dec;29(12):1650-7 [16311856.001]
  • [Cites] Radiology. 2006 Feb;238(2):560-9 [16436817.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):582-94 [16523362.001]
  • [Cites] Surg Oncol. 2005 Dec;14(4):155-78 [16517154.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Abdom Imaging. 2006 May-Jun;31(3):320-5 [16333711.001]
  • [Cites] Cancer. 2006 Jun 25;108(3):163-73 [16550572.001]
  • [Cites] Ann Surg Oncol. 2006 Jul;13(7):955-60 [16788757.001]
  • [Cites] Virchows Arch. 2006 Jul;449(1):112-6 [16639605.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(4):280-5 [16858538.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] J Pathol. 2006 Sep;210(1):42-8 [16794990.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):572-82 [16998366.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1561-9 [17122512.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2567-75 [17054109.001]
  • [Cites] Pancreatology. 2006;6(6):626-34 [17135772.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]
  • [Cites] JOP. 2007;8(2):206-13 [17356245.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):242-8 [17097223.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Apr;5(4):489-95 [17350894.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):338-44 [17458608.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):243-54 [17520199.001]
  • [Cites] Gut. 2007 Aug;56(8):1086-90 [17127707.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10 [17631133.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):266-79 [17785207.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):199-205 [17909912.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):101-9 [17917784.001]
  • [Cites] World J Surg. 2008 Feb;32(2):271-8; discussion 279-80 [18027021.001]
  • [Cites] Ann Surg. 2009 Mar;249(3):440-7 [19247032.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2009;23(1):35-48 [19258185.001]
  • [Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]
  • [Cites] Mol Biol Cell. 2009 Apr;20(7):1992-2003 [19225151.001]
  • [Cites] Pancreatology. 2009;9(1-2):34-44 [19077453.001]
  • [Cites] Am J Gastroenterol. 2009 Sep;104(9):2175-81 [19491823.001]
  • [Cites] Radiology. 2009 Oct;253(1):106-15 [19703865.001]
  • [Cites] Pancreatology. 2009;9(5):631-8 [19657218.001]
  • [Cites] Gastroenterology. 2010 Feb;138(2):531-40 [19818780.001]
  • [Cites] Ann Surg. 2010 Mar;251(3):477-82 [20142730.001]
  • [Cites] Ann Surg. 2010 Mar;251(3):470-6 [20142731.001]
  • [Cites] Ann Surg Oncol. 2010 Apr;17(4):1168-76 [19936839.001]
  • [Cites] Pancreas. 2010 Apr;39(3):308-14 [19924021.001]
  • [Cites] Gastrointest Endosc. 2003 Jul;58(1):59-64 [12838222.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Langenbecks Arch Surg. 2003 Dec;388(6):392-400 [12910422.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):839-48 [15223952.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):168-78 [15185076.001]
  • (PMID = 21147870.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3227924
  •  go-up   go-down


88. Rodriguez JR, Salvia R, Crippa S, Warshaw AL, Bassi C, Falconi M, Thayer SP, Lauwers GY, Capelli P, Mino-Kenudson M, Razo O, McGrath D, Pederzoli P, Fernández-Del Castillo C: Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology; 2007 Jul;133(1):72-9; quiz 309-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Sixty-six patients (45.5%) had adenoma, 47 (32%) borderline tumors, 16 (11%) carcinoma in situ, and 16 (11%) invasive carcinoma.
  • After a mean follow-up of 45 months, the 5-year disease-specific survival for branch-duct IPMNs with noninvasive neoplasms was 100% and, for invasive cancer, was 63%.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma in Situ / mortality. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Postoperative Complications / mortality. Practice Guidelines as Topic / standards. Survival Analysis


89. Schwartz AM, Henson DE: Familial and sporadic pancreatic carcinoma, epidemiologic concordance. Am J Surg Pathol; 2007 Apr;31(4):645-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma in Situ / epidemiology. Genetic Predisposition to Disease. Pancreatic Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Pancreatic carcinoma, familial.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • (PMID = 17414117.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


90. Liu W, Liu Y, Zhu J, Wright E, Ding I, Rodgers GP: Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma. Clin Cancer Res; 2008 Feb 15;14(4):1041-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: The expression of hGC-1 in colon adenocarcinoma tissues was examined by dot-blot analysis, in situ hybridization, and immunohistochemistry.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Granulocyte Colony-Stimulating Factor / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Adhesion / physiology. Cell Line, Tumor. Cell Movement / physiology. DNA Methylation. DNA Mutational Analysis. Disease Progression. Female. Gene Expression. HT29 Cells. Humans. Immunoblotting. Immunohistochemistry. In Situ Hybridization. Kaplan-Meier Estimate. Male. Microscopy, Confocal. Middle Aged. Promoter Regions, Genetic. RNA, Messenger / analysis

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281536.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


91. Tsiambas E, Karameris A, Dervenis C, Lazaris AC, Giannakou N, Gerontopoulos K, Patsouris E: HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP; 2006;7(3):283-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
  • CONTEXT: HER2/neu overexpression is observed in many cancers including pancreatic ductal adenocarcinoma.
  • DESIGN: Using tissue microarray technology, fifty histologically confirmed pancreatic ductal adenocarcinomas were cored twice and re-embedded in one paraffin block.
  • Immunohistochemistry (clone TAB 250) and chromogenic (HER2/neu amplification Spot Light kit) in situ hybridization protocols were performed.
  • CONCLUSION: Our results indicate that a subset of pancreatic ductal adenocarcinomas is characterized by HER2/neu gene amplification.
  • Furthermore, evaluation of HER2/neu protein expression based on digital image analysis and not only on conventional eye microscopy improves the accuracy and reliability of immunohistochemical estimation, although that does not demonstrate clinical significance and prognostic value in pancreatic ductal adenocarcinoma.
  • [MeSH-minor] Aged. Aneuploidy. Chromosomes, Human, Pair 17. Female. Humans. Image Processing, Computer-Assisted. Immunohistochemistry / methods. In Situ Hybridization. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Reproducibility of Results. Staining and Labeling


92. Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y, Chen J: Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J; 2005 Nov;19(13):1884-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EphA2 belongs to a unique family of receptor tyrosine kinases that play critical roles in development and disease.
  • Since EphA2 is required for ephrin-A1 ligand-induced vascular remodeling and is overexpressed in a variety of vascularized human adenocarcinomas, we assessed tumor angiogenesis and metastatic progression in EphA2-deficient host animals.
  • 4T1 metastatic mammary adenocarcinoma cells transplanted subcutaneously and orthotopically into EphA2-deficient female mice displayed decreased tumor volume, tumor cell survival, microvascular density, and lung metastasis relative to tumor-bearing littermate controls.
  • [MeSH-minor] Adenocarcinoma / metabolism. Animals. Antigens, CD31 / biosynthesis. Cell Line, Tumor. Cell Movement. Cell Survival. Cell Transplantation. Collagen / chemistry. Disease Progression. Drug Combinations. Endothelium, Vascular / pathology. Ephrin-A1 / metabolism. Female. In Situ Nick-End Labeling. Lac Operon. Laminin / chemistry. Ligands. Lung / pathology. Mice. Mice, Inbred BALB C. Mice, Nude. Mice, Transgenic. Microcirculation. Microscopy, Fluorescence. Models, Biological. Models, Statistical. Mutation. Neoplasm Metastasis. Neoplasm Transplantation. Neovascularization, Pathologic. Oxygen / metabolism. Phenotype. Proteoglycans / chemistry. Receptors, Eph Family / metabolism. rac1 GTP-Binding Protein / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166198.001).
  • [ISSN] 1530-6860
  • [Journal-full-title] FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • [ISO-abbreviation] FASEB J.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA95004
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Drug Combinations; 0 / Ephrin-A1; 0 / Laminin; 0 / Ligands; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen; EC 2.7.10.1 / Receptor, EphA2; EC 2.7.10.1 / Receptors, Eph Family; EC 3.6.5.2 / rac1 GTP-Binding Protein; S88TT14065 / Oxygen
  •  go-up   go-down


93. Pavlakis K, Kountourakis P, Stathopoulos E, Psyrri A, Rontogianni D, Kafousi M, Derivianaki M, Xiros N, Pectasides D, Economopoulos T: Her-2 protein expression, cellular localization, and gene amplification in colorectal carcinoma. Appl Immunohistochem Mol Morphol; 2007 Dec;15(4):441-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Her-2 protein expression and gene amplification were assessed in paraffin sections from 106 primary colorectal adenocarcinoma cases using immunohistochemistry and fluorescence in situ hybridization.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091388.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


94. Ganta S, Amiji M: Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm; 2009 May-Jun;6(3):928-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we have examined augmentation of therapeutic efficacy upon coadministration of paclitaxel (PTX) and curcumin (CUR), an inhibitor of nuclear factor kappa B (NFkappaB) as well as a potent down-regulator of ABC transporters, in wild-type SKOV3 and drug resistant SKOV3(TR) human ovarian adenocarcinoma cells.
  • [MeSH-minor] Apoptosis / drug effects. Blotting, Western. Cell Line, Tumor. Flow Cytometry. Humans. In Situ Nick-End Labeling. Molecular Structure. NF-kappa B / antagonists & inhibitors

  • NCI caNanoLab Data Portal. supplemental materials - caNanoLab samples curated from the publication .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CURCUMIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19278222.001).
  • [ISSN] 1543-8384
  • [Journal-full-title] Molecular pharmaceutics
  • [ISO-abbreviation] Mol. Pharm.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA119617
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / NF-kappa B; IT942ZTH98 / Curcumin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


95. Saglam A, Bozdag G, Kuzey GM, Kuçukali T, Ayhan A: Four synchronous female genital malignancies: the ovary, cervix, endometrium and fallopian tube. Arch Gynecol Obstet; 2008 Jun;277(6):557-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To present a unique case of a 63 year-old woman with coexistent adenocarcinoma of the ovary, endometrium, cervix and fallopian tube.
  • The pale infiltrative lesion in the cervix also turned out to be an adenocarcinoma of the endocervical type with deep stromal invasion and areas of diffuse glandular dysplasia and in-situ glandular neoplasia at the periphery.
  • Besides, several sections from the left fallopian tube uncovered diffuse dysplasia in the lining epithelium and a focus of adenocarcinoma with papillary and cribriform pattern.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology


96. Song Y, Huang J, Wang JW: [Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma]. Chin J Cancer; 2010 Jan;29(1):76-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The HER2/neu status in 83 advanced gastric carcinomas was evaluated using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
  • [MeSH-major] Adenocarcinoma. Genes, erbB-2. Receptor, ErbB-2 / metabolism. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038314.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


97. Ikeda S, Maeshiro K, Ryu S, Ogata K, Yasunami Y, Nakayama Y, Hamada Y: Diagnosis of small pancreatic cancer by endoscopic balloon-catheter spot pancreatography: an analysis of 29 patients. Pancreas; 2009 May;38(4):e102-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of small pancreatic cancer by endoscopic balloon-catheter spot pancreatography: an analysis of 29 patients.
  • OBJECTIVES: The diagnosis of small pancreatic cancer remains difficult.
  • Of the 175 patients, 23 (13%) had invasive carcinoma 2 cm or smaller based on histological measurements, 3 intraductal papillotubular adenocarcinoma, and 3 carcinoma in situ (CIS).
  • A definite diagnosis was obtained based on the findings of main duct stenosis or obstruction with marked stricture of the branch ducts (n = 18) and a filling defect in the main duct (n = 2).
  • CONCLUSIONS: Balloon spot pancreatography is an essential tool for the diagnosis of small ductal pancreatic cancer, and it also makes it possible to locate CIS lesions of the branch ducts.
  • [MeSH-major] Catheterization. Cholangiopancreatography, Endoscopic Retrograde / methods. Pancreas / pathology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Acute Disease. Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Carcinoma, Pancreatic Ductal / diagnosis. Female. Humans. Male. Middle Aged. Pancreatitis / diagnosis. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287333.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Kietpeerakool C, Srisomboon J, Khunamornpong S, Siriaunkgul S, Sukkawattananon W: How can the overtreatment rate of "see and treat" approach be reduced in women with high-grade squamous intraepithelial lesion on cervical cytology? Asian Pac J Cancer Prev; 2007 Apr-Jun;8(2):206-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How can the overtreatment rate of "see and treat" approach be reduced in women with high-grade squamous intraepithelial lesion on cervical cytology?
  • BACKGROUND: The aim of this study was to determine the incidence and predictors of overtreatment in "see and treat" approach using loop electrosurgical excision procedure (LEEP) in women with high-grade squamous intraepithelial lesion (HSIL) on cervical cytology.
  • Of 446 women, histologically-confirmed HSIL, invasive cancer, low-grade squamous intraepithelial lesions, and adenocarcinoma in situ were detected in 330 (74.0%), 76 (17.0%), 9 (2.0%), and 5 (1.1%), respectively.

  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696732.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


99. Konski A: Clinical and economic outcomes analyses of women developing breast cancer in a managed care organization. Am J Clin Oncol; 2005 Feb;28(1):51-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Administrative claims records were linked to clinical information obtained from hospital and tumor registry data for women diagnosed with adenocarcinoma or carcinoma in situ of the breast between 1990 and 1997.


100. Karamitopoulou E, Zlobec I, Tornillo L, Carafa V, Schaffner T, Brunner T, Borner M, Diamantis I, Zimmermann A, Terracciano L: Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN). Pathology; 2010 Apr;42(3):229-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN).
  • AIMS: Pancreatic cancer is an aggressive tumour following a multistep progression model through precursors called pancreatic intraepithelial neoplasia (PanIN).
  • METHODS: We analysed the expression of p21, p27, p53 and Ki-67, in 210 ductal pancreatic adenocarcinomas, 40 PanIN-3 cases and 40 normal controls combined in a tissue microarray.
  • RESULTS: Our study revealed a differential p27, p21, p53, and Ki-67 expression between ductal adenocarcinoma, PanIN-3 and normal pancreas. p27 expression progressively decreased from normal pancreas to PanIN and to pancreatic cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma in Situ / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Cell Cycle Proteins / biosynthesis. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20350215.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53; 0 / p27 antigen; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down






Advertisement